A FLORIDA CORPORATION) [___] SHARES OF COMMON STOCK UNDERWRITING AGREEMENT
EXHIBIT 1.1
BABY UNIVERSE, INC.
(A FLORIDA CORPORATION)
[___] SHARES OF COMMON STOCK
[___] SHARES OF COMMON STOCK
Dated: August ___, 2005
Baby Universe, Inc.
(a Florida corporation)
[_________] Shares of Common Stock
(Par Value $.001 Per Share)
(a Florida corporation)
[_________] Shares of Common Stock
(Par Value $.001 Per Share)
GUNNALLEN FINANCIAL, INC.
WEDBUSH XXXXXX SECURITIES
As Representatives of the several
Underwriters to be named in the
Within-mentioned Underwriting Agreement
c/o GunnAllen Financial, Inc.
0000 Xxxx Xxxxxx Xxxxxx
Xxxxx, Xxxxxxx 00000
WEDBUSH XXXXXX SECURITIES
As Representatives of the several
Underwriters to be named in the
Within-mentioned Underwriting Agreement
c/o GunnAllen Financial, Inc.
0000 Xxxx Xxxxxx Xxxxxx
Xxxxx, Xxxxxxx 00000
Ladies and Gentlemen:
Baby Universe, Inc., a Florida corporation (the “Company”), and Wyndcrest Baby Universe
Holdings, LLC, Wyndcrest Baby Universe Holdings II, LLC, Wyndcrest Baby Universe Holdings III, LLC,
Xxxxxxxx Xxxxx and Xxxx Xxxxx (the “Selling Shareholders”) confirm their respective agreements with
GunnAllen Financial, Inc. (“GAF”) and the other Underwriters named in Schedule A hereto
(collectively, the “Underwriters,” which term shall also include any underwriter substituted as
hereinafter provided in Section 10 hereof), for whom GAF and Wedbush Xxxxxx Securities are acting
as representatives (in such capacity, the “Representatives”), with respect to (i) the issue and
sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the
respective numbers of shares of Common Stock, par value $.001 per share, of the Company (“Common
Stock”) set forth in Schedule A hereto and (ii) the grant by the Selling Shareholders, acting
severally and not jointly, to the Underwriters, acting severally and not jointly, of the option
described in Section 2(b) hereof to purchase all or any part of [300,000] additional shares of
Common Stock to cover overallotments, if any. The aforesaid [2,000,000] shares of Common Stock (the
“Initial Securities”) to be purchased by the Underwriters and all or any part of the [300,000]
shares of Common Stock subject to the option described in Section 2(b) hereof (the “Option
Securities”) are hereinafter called, collectively, the “Securities.”
The Company understands that the Underwriters propose to make a public offering of the
Securities as soon as the Representatives deem advisable after this Agreement has been executed and
delivered.
The Company and the Underwriters agree that up to [100,000] shares of the Securities to be
purchased by the Underwriters (the “Reserved Securities”) shall be reserved for sale by the
Underwriters to certain eligible employees and persons having business relationships with the
Company (the “Invitees”), as part of the distribution of the Securities by the Underwriters,
subject to the terms of this Agreement, the applicable rules, regulations and interpretations of
the National Association of Securities Dealers, Inc. and all other applicable laws, rules and
regulations. To the extent that such Reserved Securities are not orally confirmed for purchase by
Invitees by the end of the first business day after the
1
date of this Agreement, such Reserved Securities may be offered to the public as part of the
public offering contemplated hereby.
The Company has filed with the Securities and Exchange Commission (the “Commission”) a
registration statement on Form S-1 (No. 333-124395), including the related preliminary prospectus
or prospectuses, covering the registration of the Securities under the Securities Act of 1933, as
amended (the “1933 Act”). Promptly after execution and delivery of this Agreement, the Company
will prepare and file a prospectus in accordance with the provisions of Rule 430A (“Rule 430A”) of
the rules and regulations of the Commission under the 1933 Act (the “1933 Act Regulations”) and
paragraph (b) of Rule 424 (“Rule 424(b)”) of the 1933 Act Regulations. The information included in
such prospectus that was omitted from such registration statement at the time it became effective
but that is deemed to be part of such registration statement at the time it became effective
pursuant to paragraph (b) of Rule 430A is referred to as “Rule 430A Information.” Each prospectus
used before such registration statement became effective, and any prospectus that omitted the Rule
430A Information, that was used after such effectiveness and prior to the execution and delivery of
this Agreement, is herein called a “preliminary prospectus.” Such registration statement,
including the exhibits and any schedules thereto, at the time it became effective, and including
the Rule 430A Information, is herein called the “Registration Statement.” Any registration
statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein referred to as the
“Rule 462(b) Registration Statement,” and after such filing the term “Registration Statement” shall
include the Rule 462(b) Registration Statement. The final prospectus in the form first furnished
to the Underwriters for use in connection with the offering of the Securities is herein called the
“Prospectus.” For purposes of this Agreement, all references to the Registration Statement, any
preliminary prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall
be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering,
Analysis and Retrieval system (“XXXXX”).
SECTION 1. Representations and Warranties.
(a) Representations and Warranties by the Company. The Company represents and warrants to each
Underwriter as of the date hereof, as of the Closing Time referred to in Section 2(c) hereof, and
as of each Date of Delivery (if any) referred to in Section 2(b) hereof, and agrees with each
Underwriter, as follows:
i. Compliance with Registration Requirements. Each of the Registration
Statement and any Rule 462(b) Registration Statement and any post-effective amendment
thereto has become effective under the 1933 Act and no stop order suspending the
effectiveness of the Registration Statement, any Rule 462(b) Registration Statement or any
post-effective amendment thereto has been issued under the 1933 Act and no proceedings for
that purpose have been instituted or are pending or, to the knowledge of the Company, are
contemplated by the Commission, and the Company has complied with any request on the part of
the Commission for additional information.
At the respective times the Registration Statement, any Rule 462(b) Registration
Statement and any post-effective amendments thereto became effective and at the Closing Time
(and, if any Option Securities are purchased, at the Date of Delivery), the Registration
Statement, the Rule 462(b) Registration Statement and any amendments and supplements thereto
complied and will comply in all material respects with the requirements of the 1933 Act and
the 1933 Act Regulations and did not and will not contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading. Neither the Prospectus nor any amendments or
supplements thereto at the time the Prospectus or any such amendment or supplement was
issued and at the Closing Time (and, if any
2
Option Securities are purchased, at the Date of Delivery), included, or will include an
untrue statement of a material fact or omitted or will omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The representations and warranties in this subsection
shall not apply to statements in or omissions from the Registration Statement or Prospectus
made in reliance upon and in conformity with written information furnished to the Company by
any Underwriter through GAF expressly for use in the Registration Statement (or any
amendment thereto) or the Prospectus (or any amendment or supplement thereto).
Each preliminary prospectus and the prospectus filed as part of the Registration
Statement as originally filed or as part of any amendment thereto complied when so filed in
all material respects with the 1933 Act Regulations and each preliminary prospectus and the
Prospectus delivered to the Underwriters for use in connection with this offering was
identical to the electronically transmitted copies thereof filed with the Commission
pursuant to XXXXX, except to the extent permitted by Regulation S-T.
ii. Independent Accountants. The accountants who certified the financial
statements and supporting schedules included in the Registration Statement are independent
public accountants as required by the 1933 Act and the 1933 Act Regulations.
iii. Financial Statements. The financial statements included in the
Registration Statement and the Prospectus, together with the related schedules and notes,
present fairly the financial position of the Company and its consolidated subsidiaries at
the dates indicated and the statement of operations, stockholders’ equity and cash flows of
the Company and its consolidated subsidiaries for the periods specified; said financial
statements have been prepared in conformity with generally accepted accounting principles
(“GAAP”) applied on a consistent basis throughout the periods involved. The supporting
schedules included in the Registration Statement present fairly in accordance with GAAP the
information required to be stated therein. The selected financial data and the summary
financial information included in the Prospectus present fairly the information shown
therein and have been compiled an a basis consistent with that of the audited financial
statements included in the Registration Statement.
iv. No Material Adverse Change in Business. Since the respective dates as of
which information is given in the Registration Statement and the Prospectus, except as
otherwise stated therein, (A) there has been no material adverse change in the condition,
financial or otherwise, or in the earnings, business affairs or business prospects of the
Company and its subsidiaries considered as one enterprise, whether or not arising in the
ordinary course of business (a “Material Adverse Effect”), (B) there have been no
transactions entered into by the Company or any of its subsidiaries, other than those in the
ordinary course of business, which are material with respect to the Company and its
subsidiaries considered as one enterprise, and (C) there has been no dividend or
distribution of any kind declared, paid or made by the Company on any class of its capital
stock.
v. Good Standing of the Company. The Company has been duly organized and is
validly existing as a corporation in good standing under the laws of the State of Florida
and has corporate power and authority to own, lease and operate its properties and to
conduct its business as described in the Prospectus and to enter into and perform its
obligations under this Agreement; and the Company is duly qualified as a foreign corporation
to transact business and is in good standing in each other jurisdiction in which such
qualification is required, whether by reason of
3
the ownership or leasing of property or the conduct of business, except where the
failure so to qualify or to be in good standing would not result in a Material Adverse
Effect.
vi. Good Standing of Subsidiaries. Each “significant subsidiary” of the
Company (as such term is defined in Rule 1-02 of Regulation S-X) (each a “Subsidiary” and,
collectively, the “Subsidiaries”) has been duly organized and is validly existing as a
corporation in good standing under the laws of the jurisdiction of its incorporation, has
corporate power and authority to own, lease and operate its properties and to conduct its
business as described in the Prospectus and is duly qualified as a foreign corporation to
transact business and is in good standing in each jurisdiction in which such qualification
is required, whether by reason of the ownership or leasing of property or the conduct of
business, except where the failure so to qualify or to be in good standing would not result
in a Material Adverse Effect; except as otherwise disclosed in the Registration Statement,
all of the issued and outstanding capital stock of each such Subsidiary has been duly
authorized and validly issued, is fully paid and non-assessable and is owned by the Company,
directly or through subsidiaries, free and clear of any security interest, mortgage, pledge,
lien, encumbrance, claim or equity; none of the outstanding shares of capital stock of any
Subsidiary was issued in violation of the preemptive or similar rights of any security
holder of such Subsidiary. The only subsidiaries of the Company are the subsidiaries listed
on Exhibit 21 to the Registration Statement.
vii. Capitalization. The authorized, issued and outstanding capital stock of
the Company is as set forth in the Prospectus in the column entitled “Actual” under the
caption “Capitalization” (except for subsequent issuances, if any, pursuant to this
Agreement, pursuant to reservations, agreements or employee benefit plans referred to in the
Prospectus or pursuant to the exercise of convertible securities or options referred to in
the Prospectus). The shares of issued and outstanding capital stock of the Company are
validly issued and are fully paid and non-assessable; none of the outstanding shares of
capital stock of the Company was issued in violation of the preemptive or other similar
rights of any securityholder of the Company.
viii. Authorization of Agreement. This Agreement has been duly authorized,
executed and delivered by the Company.
ix. Authorization and Description of Securities. The Securities have been duly
authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when
issued and delivered by the Company pursuant to this Agreement against payment of the
consideration set forth herein, will be validly issued and fully paid and non-assessable;
the Common Stock conforms to all statements relating thereto contained in the Prospectus and
such description conforms to the rights set forth in the instruments defining the same; no
holder of the Securities will be subject to personal liability by reason of being such a
holder; and the issuance of the Securities is not subject to the preemptive or other similar
rights of any securityholder of the Company.
x. Absence of Defaults and Conflicts. Neither the Company nor any of its
subsidiaries is in violation of its charter or by-laws or in default in the performance or
observance of my obligation, agreement, covenant or condition contained in any contract,
indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement
or instrument to which the Company or any of its subsidiaries is a party or by which it or
any of them may be bound, or to which any of the property or assets of the Company or any
subsidiary is subject (collectively, “Agreements and Instruments”) except for such defaults
that would not result in a Material Adverse Effect; and the execution, delivery and
performance of this Agreement and the
4
consummation of the transactions contemplated herein and in the Registration Statement
(including the issuance and sale of the Securities and the use of the proceeds from the sale
of the Securities as described in the Prospectus under the caption “Use of Proceeds”) and
compliance by the Company with its obligations hereunder have been duly authorized by all
necessary corporate action and do not and will not, whether with or without the giving of
notice or passage of time or both, conflict with or constitute a breach of, or default or
Repayment Event (as defined below) under, or result in the creation or imposition of any
lien, charge or encumbrance upon any property or assets of the Company or any subsidiary
pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults
or Repayment Events or liens, charges or encumbrances that would not result in a Material
Adverse Effect), nor will such action result in any violation of the provisions of the
charter or by-laws of the Company or any subsidiary or any applicable law, statute, rule,
regulation, judgment, order, writ or decree of any government, government instrumentality or
court, domestic or foreign, having jurisdiction over the Company or any subsidiary or any of
their assets, properties or operations. The Company has not sent or received any
communication regarding termination of, or intent not to renew, any of the Agreements and
Instruments referred to or described in, or filed as an exhibit to, the Registration
Statement, and no such termination or non-renewal has been threatened by the Company or, to
the Company’s knowledge, any other party to any such Agreement or Instrument. As used
herein, a “Repayment Event” means any event or condition which gives the holder of any note,
debenture or other evidence of indebtedness (or any person acting on such holder’s behalf)
the right to require the repurchase, redemption or repayment of all or a portion of such
indebtedness by the Company or any subsidiary.
xi. Absence of Labor Dispute. No labor dispute with the employees of the
Company or any subsidiary exists or, to the knowledge of the Company, is imminent, and the
Company is not aware of any existing or imminent labor disturbance by the employees of any
of its or any subsidiary’s principal suppliers, manufacturers, customers or contractors,
which, in either case, would result in a Material Adverse Effect.
xii. Absence of Proceedings. There is no action, suit, proceeding, inquiry or
investigation before or brought by any court or governmental agency or body, domestic or
foreign, now pending, or, to the knowledge of the Company, threatened, against or affecting
the Company or any subsidiary, which is required to be disclosed in the Registration
Statement (other than as disclosed therein), or which might result in a Material Adverse
Effect, or which might materially and adversely affect the properties or assets thereof or
the consummation of the transactions contemplated in this Agreement or the performance by
the Company of its obligations hereunder; the aggregate of all pending legal or governmental
proceedings to which the Company or any subsidiary is a party or of which any of their
respective property or assets is the subject which are not described in the Registration
Statement, including ordinary routine litigation incidental to the business, could not
result in a Material Adverse Effect.
xiii. Accuracy of Exhibits. There are no contracts or documents which are
required to be described in the Registration Statement or the Prospectus or to be filed as
exhibits thereto which have not been so described and filed as required.
xiv. Possession of Intellectual Property. The Company and its subsidiaries own
or possess, or can acquire on reasonable terms, adequate patents, patent rights, licenses,
inventions, copyrights, know-how (including trade secrets and other unpatented and/or
unpatentable proprietary or confidential information, systems or procedures), trademarks,
service marks, trade names or other intellectual property (collectively, “Intellectual
Property”) necessary to carry on
5
the business now operated by them, and neither the Company nor any of its subsidiaries
has received any notice or is otherwise aware of any infringement of or conflict with
asserted rights of others with respect to any Intellectual Property or of any facts or
circumstances which would render any Intellectual Property invalid or inadequate to protect
the interest of the Company or any of its subsidiaries therein, and which infringement or
conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or
inadequacy, singly or in the aggregate, would result in a Material Adverse Effect.
xv. Absence of Further Requirements. No filing with, or authorization,
approval, consent, license, order, registration, qualification or decree of, any court or
governmental authority or agency is necessary or required for the performance by the Company
of its obligations hereunder, in connection with the offering, issuance or sale of the
Securities hereunder or the consummation of the transactions contemplated by this Agreement,
except such as have been already obtained or as may be required under the 1933 Act or the
1933 Act Regulations or state securities laws.
xvi. Absence of Manipulation. Neither the Company nor any affiliate of the
Company has taken, nor will the Company or any affiliate take, directly or indirectly, any
action which is designed to or which has constituted or which would be expected to cause or
result in stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Securities.
xvii. Possession of Licenses and Permits. The Company and its subsidiaries
possess such permits, licenses, approvals, consents and other authorizations (collectively,
“Governmental Licenses”) issued by the appropriate federal, state, local or foreign
regulatory agencies or bodies necessary to conduct the business now operated by them, except
where the failure so to possess would not, singly or in the aggregate, result in a Material
Adverse Effect; the Company and its subsidiaries are in compliance with the terms and
conditions of all such Governmental Licenses, except where the failure so to comply would
not, singly or in the aggregate, result in a Material Adverse Effect; all of the
Governmental Licenses are valid and in full force and effect, except when the invalidity of
such Governmental Licenses or the failure of such Governmental Licenses to be in full force
and effect would not, singly or in the aggregate, result in a Material Adverse Effect; and
neither the Company nor any of its subsidiaries has received any notice of proceedings
relating to the revocation or modification of any such Governmental Licenses which, singly
or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would
result in a Material Adverse Effect.
xviii. Title to Property. The Company and its subsidiaries have good and
marketable title to all real property owned by the Company and its subsidiaries and good
title to all other properties owned by them, in each case, free and clear of all mortgages,
pledges, liens, security interests, claims, restrictions or encumbrances of any kind except
such as (A) are described in the Prospectus or (B) do not, singly or in the aggregate,
materially affect the value of such property and do not interfere with the use made and
proposed to be made of such property by the Company or any of its subsidiaries; and all of
the leases and subleases material to the business of the Company and its subsidiaries,
considered as one enterprise, and under which the Company or any of its subsidiaries holds
properties described in the Prospectus, are in full force and effect, and neither the
Company nor any subsidiary has any notice of any material claim of any sort that has been
asserted by anyone adverse to the rights of the Company or any subsidiary under any of the
leases or subleases mentioned above, or affecting or questioning the rights of the Company
or
6
such subsidiary to the continued possession of the leased or subleased premises under
any such lease or sublease.
xix. Investment Company Act. The Company is not and, after giving effect to the
offering and sale of the Securities, will not be an “investment company” or an entity
“controlled” by an “investment company,” as such terms are defined in the Investment Company
Act of 1940, as amended (the “Investment Company Act”).
xx. Environmental Laws. Except as described in the Registration Statement and
except as would not, singly or in the aggregate, result in a Material Adverse Effect, (A)
neither the Company nor any of its subsidiaries is in violation of any federal, state, local
or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or
any judicial or administrative interpretation thereof, including any judicial or
administrative order, consent, decree or judgment, relating to pollution or protection of
human health, the environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including, without limitation,
laws and regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum
products, asbestos-containing materials or mold (collectively, “Hazardous Materials”) or to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or
handling of Hazardous Materials (collectively, “Environmental Laws”), (B) the Company and
its subsidiaries have all permits, authorizations and approvals required under any
applicable Environmental Laws and are each in compliance with their requirements, (C) there
are no pending or threatened administrative, regulatory or judicial actions, suits, demands,
demand letters, claims, liens, notices of noncompliance or violation, investigation or
proceedings relating to any Environmental Law against the Company or any of its subsidiaries
and (D) there are no events or circumstances that would reasonably be expected to form the
basis of an order for clean-up or remediation, or an action, suit or proceeding by any
private party or governmental body or agency, against or affecting the Company or any of its
subsidiaries relating to Hazardous Materials or any Environmental Laws.
xxi. Registration Rights. There are no persons with registration rights or
other similar rights to have any securities registered pursuant to the Registration
Statement or otherwise registered by the Company under the 1933 Act.
xxii. Internal Controls. The Company and each of the Subsidiaries maintains a
system of internal accounting controls sufficient to provide reasonable assurance that (A)
transactions are executed in accordance with management’s general or specific authorization;
(B) transactions are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles and to maintain accountability for
assets; (C) access to assets is permitted only in accordance with management’s general or
specific authorization; and (D) the recorded accountability for assets is compared with
existing assets at reasonable intervals and appropriate action is taken with respect to any
differences.
The Company has established and maintains disclosure controls and procedures (as such
term is defined in Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as
amended (the “1934 Act”)); such disclosure controls and procedures are designed to ensure
that material information relating to the Company, including its consolidated subsidiaries,
is made known to the Company’s Chief Executive Officer and its Chief Financial Officer by
others within those entities, and such disclosure controls and procedures are effective to
perform the functions for which they were established; the Company’s auditors and the Audit
Committee of the Board of
7
Directors have been advised of (A) any significant deficiencies in the design or
operation of internal controls which could adversely affect the Company’s ability to record,
process, summarize, and report financial data; and (B) any fraud, whether or not material,
that involves management or other employees who have a role in the Company’s internal
controls; any material weaknesses in internal controls have been identified for the
Company’s auditors; and since the date of the most recent evaluation of such disclosure
controls and procedures, there have been no significant changes in internal controls or in
other factors that could significantly affect internal controls, including any corrective
actions with regard to significant deficiencies and material weaknesses.
xxiii. Loans to Officers or Directors. The Company has provided to the
Representatives true, correct, and complete copies of all documentation pertaining to any
extension of credit in the form of a personal loan made, directly or indirectly, by the
Company to any director or executive officer of the Company, or to any family member or
affiliate of any director or executive officer of the Company; and since July 30, 2002, the
Company has not, directly or indirectly, including through any subsidiary: (A) extended
credit, arranged to extend credit, or renewed any extension of credit, in the form of a
personal loan, to or for any director or executive officer of the Company, or to or for any
family member or affiliate of any director or executive officer of the Company; or (B) made
any material modification, including any renewal thereof, to any term of any personal loan
to any director or executive officer of the Company, or any family member or affiliate of
any director or executive officer, which loan was outstanding on July 30, 2002.
xxiv. Statistical Data. Any statistical and market-related data included in
the Registration Statement and the Prospectus are based on or derived from sources that the
Company believes to be reliable and accurate, and the Company has obtained the written
consent to the use of such data from such sources to the extent required.
xxv. Unlawful Payments. Neither the Company nor any of its subsidiaries nor,
to the Company’s knowledge, any employee or agent of the Company or its subsidiaries has
made any payment of funds of the Company or its subsidiaries or received or retained any
funds in violation of any law, rule or regulation.
xxvi. Reserved Securities. The Registration Statement, the Prospectus and any
preliminary prospectus comply, and any further amendments or supplements thereto will
comply, with any applicable laws or regulations of any foreign jurisdiction in which the
Prospectus or any preliminary prospectus is distributed in connection with the Reserved
Securities; and no approval, authorization, consent or order of or filing with any
governmental or regulatory commission, board, body, authority or agency, other than those
obtained, is required in connection with the offering of the Reserved Securities in any
jurisdiction where the Reserved Securities are being offered. The Company has not offered,
or caused the Underwriters to offer Reserved Securities to any person with the intent to
influence unlawfully (A) a customer or supplier of the Company or any of the Subsidiaries to
alter the customer’s or supplier’s level or type of business with the Company or any of the
Subsidiaries, or (B) a trade journalist or publication to write or publish favorable
information about the Company or any of the Subsidiaries or any of their respective products
or services.
xxvii. Tax Returns. All tax returns required to be filed by the Company and
each of the Subsidiaries have been filed, and all taxes and other assessments of a similar
nature (whether imposed directly or through withholding) including any interest, additions
to tax or penalties
8
applicable thereto due or claimed to be due from such entities have been paid, other
than those being contested in good faith and for which adequate reserves have been provided.
xxviii. Insurance. The Company and each of the Subsidiaries maintains
insurance covering its properties, operations, personnel and businesses as the Company deems
adequate, including, but not limited to, directors’ and officers’ insurance; such insurance
insures against such losses and risks to an extent which is adequate in accordance with
customary industry practice to protect the Company and the Subsidiaries and their
businesses; all such insurance is fully in force on the date hereof and will be fully in
force. The Company has not been refused any insurance coverage sought or applied for and
the Company has no reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business at a cost that would not
result in a material adverse effect.
xxix. Brokers’ Commissions. Except as disclosed in the Registration Statement
or Prospectus, there are no contracts, agreements or understandings between the Company and
any person that would give rise to a valid claim against the Company or any underwriter for
a brokerage commission, finder’s fee or other like payment in connection with the offering
of Securities.
xxx. Forward-looking Information. The information contained in the
Registration Statement and in the Prospectus regarding the Company’s expectations, plans and
intentions, and any other information that constitutes “forward-looking” information within
the meaning of the 1933 Act and 1934 Act were made by the Company on a reasonable basis and
reflect the Company’s good faith belief or estimate of the matters described therein.
xxxi. Doing Business in Cuba. Neither the Company nor any of its affiliates
does business with the government of Cuba or with any person or affiliate located in Cuba
within the meaning of Section 517.075, Florida Statutes and the Company agrees to comply
with such Section if before the completion of the distribution of the Securities it
commences doing such business.
xxxii. NASD Affiliations. To the Company’s knowledge, there are no
affiliations or associations between any member of the NASD and any of the Company’s
officers, directors or 5% or greater security holders, except as set forth in the
Registration Statement.
(b) Representations and Warranties by the Selling Shareholders. Each Selling Shareholder
represents and warrants to each Underwriter as of the date hereof, and as of each such Date of
Delivery in which the Selling Shareholder is selling Option Securities and agrees with each
Underwriter, as follows:
i. Accurate Disclosure. To the knowledge of the Selling Shareholder, the
representations and warranties of the Company contained in Section 1(a) hereof are true and
correct; the Selling Shareholder has reviewed and is familiar with the Registration
Statement and the Prospectus and, to the knowledge of the Selling Shareholder, neither the
Prospectus nor any amendments or supplements thereto (including any prospectus wrapper)
includes any untrue statement of a material fact or omits to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading; the Selling Shareholder is not prompted to sell the Securities to
be sold by the Selling Shareholder hereunder by any material information concerning the
Company or any subsidiary of the Company that is not set forth in the Prospectus.
9
ii. Authorization of this Agreement. This Agreement has been duly authorized,
executed and delivered by or on behalf of the Selling Shareholder.
iii. Authorization of Power of Attorney and Custody Agreement. The Power of
Attorney and Custody Agreement, in the form heretofore furnished to the Representatives (the
“Power of Attorney and Custody Agreement”), has been duly authorized, executed and delivered
by the Selling Shareholder and is the valid and binding agreement of the Selling
Shareholder.
iv. Noncontravention. The execution and delivery of this Agreement and the
Power of Attorney and Custody Agreement and the sale and delivery of the Securities to be
sold by the Selling Shareholder and the consummation of the transactions contemplated herein
and compliance by the Selling Shareholder with its obligations hereunder do not and will
not, whether with or without the giving of notice or passage of time or both, conflict with
or constitute a breach of, or default under, or result in the creation or imposition of any
tax, lien, charge or encumbrance upon the Securities to be sold by the Selling Shareholder
or any property or encumbrance upon the Securities to be sold by the Selling Shareholder or
any property or assets of the Selling Shareholder pursuant to any contract, indenture,
mortgage, deed of trust, loan or credit agreement, note, license, lease or other agreement
or instrument to which the Selling Shareholder is a party or by which the Selling
Shareholder is subject, nor will such action result in any violation of the provisions of
the charter or by-laws or other organizational instrument of the Selling Shareholder, if
applicable, or any applicable treaty, law, statute, rule, regulation, judgment, order, writ
or decree of any government, government instrumentality or court, domestic or foreign,
having jurisdiction over the Selling Shareholder or any of his or its properties.
v. Certificates Suitable for Transfer. The Securities to be sold by the
Selling Shareholder pursuant to this Agreement are certificated securities in registered
form and are not held in any securities account or by or through any securities intermediary
within the meaning of the Uniform Commercial Code as in effect in the State of Florida (the
“UCC”). Certificates for all of the Securities to be sold by the Selling Shareholder
pursuant to this Agreement, in suitable form for transfer for delivery or accompanied by
duly executed instruments of transfer or assignment in blank with signatures guaranteed,
have been placed in custody with American Stock Transfer and Trust Company (the “Custodian”)
with irrevocable conditional instructions to deliver such Securities to the Underwriters
pursuant to this Agreement.
vi. Valid Title. The Selling Shareholder has, and at the Date of Delivery will
have, valid title to the Securities to be sold by the Selling Shareholder free and clear of
all security interests, claims, liens, equities or other encumbrances and the legal right
and power, and all authorization and approval required by law, to enter into this Agreement
and the Power of Attorney and Custody Agreement and to sell, transfer and deliver the
Securities to be sold by such Selling Shareholder.
vii. Delivery of Securities. Upon the Underwriters’ acquiring possession of
the Securities to be sold by the Selling Shareholder and paying the purchase price therefor
pursuant to this Agreement, the Underwriters (assuming that no such Underwriter has notice
of any “adverse claim”, within the meaning of Chapter 678.1051 of the UCC, to such
Securities) will acquire their respective interests in such Securities (including, without
limitation, all rights that the Selling Shareholder had or has the power to transfer in such
Securities) free and clear of any adverse claim within the meaning of Chapter 678.1021 of
the UCC.
10
viii. Absence of Manipulation. The Selling Shareholder has not taken, and will
not take, directly or indirectly, any action which is designated to or which has constituted
or would be expected to cause or result in stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Securities.
ix. Absence of Further Requirements. No filing with, or consent, approval,
authorization, order, registration, qualification or decree of, any court or governmental
authority or agency, domestic or foreign, is necessary or required for the performance by
the Selling Shareholder of his or its obligations hereunder or in the Power of Attorney and
Custody Agreement, or in connection with the sale and delivery of the Securities hereunder
or the consummation of the transactions contemplated by this Agreement, except (i) such as
may be previously been made or obtained or as may be required under the 1933 Act or the 1933
Act Regulations or state securities laws and (ii) such as have been obtained under the laws
and regulations of jurisdictions outside the United States in which the Reserved Securities
are offered.
x. No Association with NASD. Neither the Selling Stockholder nor any of its
affiliates directly, or indirectly through one or more intermediaries, controls, or is
controlled by, or is under common control with, or is a person associated with (within the
meaning of Article I (dd) of the By-laws of the National Association of Securities Dealers,
Inc.), any member firm of the National Association of Securities Dealers, Inc.
(c) Officer’s Certificates. Any certificate signed by any officer of the Company or
any of its subsidiaries delivered to the Representatives or to counsel for the Underwriters shall
be deemed a representation and warranty by the Company to each Underwriter as to the matters
covered thereby and any certificate signed by or on behalf of any Selling Shareholders as such and
delivered to the Representatives or to counsel for the Underwriters pursuant to the terms of this
Agreement shall be deemed a representation and warranty of such Selling Shareholder to the
Underwriters as to the matters covered thereby.
SECTION 2. Sale and Delivery to Underwriters; Closing.
(a) Initial Securities. On the basis of the representations and warranties herein contained
and subject to the terms and conditions herein set forth, the Company agrees to sell to each
Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to
purchase from the Company, at the price per share set forth in Schedule B, the number of Initial
Securities set forth in Schedule A opposite the name of such Underwriter, plus any additional
number of Initial Securities which such Underwriter may become obligated to purchase pursuant to
the provisions of Section 10 hereof, bears to the total number of Initial Securities, subject, in
each case, to such adjustments among the Underwriters as the Representative in its sole discretion
shall make to eliminate any sales or purchases of fractional securities.
(b) Option Securities. In addition, on the basis of the representations and warranties herein
contained and subject to the terms and conditions herein set forth, the Selling Shareholders,
severally and not jointly, hereby grant an option to the Underwriters, severally and not jointly,
to purchase up to an additional [300,000] shares of Common Stock, as set forth in Schedule B, at
the price per share set forth in Schedule C, less an amount per share equal to any dividends or
distributions declared by the Company and payable on the Initial Securities but not payable on the
Option Securities. The option hereby granted will expire 30 days after the date hereof and may be
exercised in whole or in part on one occasion only for the purpose of covering overallotments which
may be made in connection with the offering and distribution of the Initial Securities upon notice
by GAF to the Selling Shareholders setting forth the
11
number of Option Securities as to which the several Underwriters are then exercising the
option and the time and date of payment and delivery for such Option Securities. The time and date
of delivery (the “Date of Delivery”) shall be determined by GAF, but shall not be later than seven
full business days after the exercise of said option, nor in any event prior to the Closing Time,
as hereinafter defined. If the option is exercised as to all or any portion of the Option
Securities, each of the Underwriters, acting severally and not jointly, will purchase that
proportion of the total number of Option Securities then being purchased which the number of
Initial Securities set forth in Schedule A opposite the name of such Underwriter bears to the total
number of Initial Securities, subject in each case to such adjustments as GAF in its discretion
shall make to eliminate any sales or purchases of fractional shares.
(c) Payment. Payment of the purchase price for, and delivery of certificates for, the Initial
Securities shall be made at the offices of Xxxxx & Xxxxxxx LLP, 000 X. Xxxxx Xxxxxx, Xxxxx 0000,
Xxxxx, Xxxxxxx 00000, or at such other place as shall be agreed upon by the Representatives and the
Company, at 9:00 A.M. (Eastern time) on the third (fourth, if the pricing occurs after 4:30 P.M.
(Eastern time) on any given day) business day after the date hereof (unless postponed in accordance
with the provisions of Section 10), or such other time not later than ten business days after such
date as shall be agreed upon by the Representatives and the Company (such time and date of payment
and delivery being herein called “Closing Time”).
In addition, in the event that any or all of the Option Securities are purchased by the
Underwriters, payment of the purchase price for, and delivery of certificates for, such Option
Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed
upon by the Representatives and the Company, on the Date of Delivery as specified in the notice
from the Representatives to the Company.
Payment shall be made to the Company and the Selling Shareholders by wire transfer of
immediately available funds to bank accounts designated by the Company and the Custodian, pursuant
to each Selling Shareholder’s Power of Attorney and Custody Agreement, as the case may be, against
delivery to the Representatives for the respective accounts of the Underwriters of certificates for
the Securities to be purchased by them. It is understood that each Underwriter has authorized the
Representatives, for its account, to accept delivery of, receipt for, and make payment of the
purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed
to purchase. GAF, individually and not as representative of the Underwriters, may (but shall not be
obligated to) make payment of the purchase price for the Initial Securities or the Option
Securities, if any, to be purchased by any Underwriter whose funds have not been received by the
Closing Time or the Date of Delivery, as the case may be, but such payment shall not relieve such
Underwriter from its obligations hereunder.
(d) Denominations; Registration. Certificates for the Initial Securities and the Option
Securities, if any, shall be in such denominations and registered in such names as the
Representatives may request in writing at least one full business day before the Closing Time or
the relevant Date of Delivery, as the case may be. The certificates for the Initial Securities and
the Option Securities, if any, will be made available for examination and packaging by the
Representatives in Tampa, Florida not later than 10:00 A.M. (Eastern time) on the business day
prior to the Closing Time or the Date of Delivery, as the case may be.
SECTION 3. Covenants of the Company. The Company covenants with each Underwriter as
follows:
(a) Compliance with Securities Regulations and Commission Requests. The Company, subject to
Section 3(b), will comply with the requirements of Rule 430A and will notify the Representatives
immediately, and confirm the notice in writing, (i) when any post-effective amendment to the
Registration
12
Statement shall become effective, or any supplement to the Prospectus or any amended
Prospectus shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of
any request by the Commission for any amendment to the Registration Statement or any amendment or
supplement to the Prospectus or for additional information, and (iv) of the issuance by the
Commission of any stop order suspending the effectiveness of the Registration Statement or of any
order preventing or suspending the use of any preliminary prospectus, or of the suspension of the
qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or
threatening of any proceedings for any of such purposes. The Company will promptly effect the
filings necessary pursuant to Rule 424(b) and will take such steps as it deems necessary to
ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was
received for filing by the Commission and, in the event that it was not, it will promptly file such
prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order
and, if any stop order is issued, to obtain the lifting thereof at the earliest possible moment.
(b) Filing of Amendments. The Company will give the Representatives notice of its intention to
file or prepare any amendment to the Registration Statement (including any filing under Rule
462(b)) or any amendment, supplement or revision to either the prospectus included in the
Registration Statement at the time it became effective or to the Prospectus, will furnish the
Representatives with copies of any such documents a reasonable amount of time prior to such
proposed filing or use, as the case may be, and will not file or use any such document to which the
Representatives or counsel for the Underwriters shall object.
(c) Delivery of Registration Statements. The Company has furnished or will deliver to the
Representatives and counsel for the Underwriters, without charge, signed copies of the Registration
Statement as originally filed and of each amendment thereto (including exhibits filed therewith or
incorporated by reference therein) and signed copies of all consents and certificates of experts,
and will also deliver to the Representatives, without charge, a conformed copy of the Registration
Statement as originally filed and of each amendment thereto (without exhibits) for each of the
Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the
Underwriters will be identical to the electronically transmitted copies thereof filed with the
Commission pursuant to XXXXX, except to the extent permitted by Regulation S-T.
(d) Delivery of Prospectuses. The Company has delivered to each Underwriter, without charge,
as many copies of each preliminary prospectus as such Underwriter reasonably requested, and the
Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The
Company will furnish to each Underwriter, without charge, during the period when the Prospectus is
required to be delivered under the 1933 Act, such number of copies of the Prospectus (as amended or
supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or
supplements thereto furnished to the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to XXXXX, except to the extent
permitted by Regulation S-T.
(e) Continued Compliance with Securities Laws. The Company will comply with the 1933 Act and
the 1933 Act Regulations so as to permit the completion of the distribution of the Securities as
contemplated in this Agreement and in the Prospectus. If at any time when a prospectus is required
by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur
or condition shall exist as a result of which it is necessary, in the opinion of counsel for the
Underwriters or for the Company, to amend the Registration Statement or amend or supplement the
Prospectus in order that the Prospectus will not include any untrue statements of a material fact
or omit to state a material fact necessary in order to make the statements therein not misleading
in the light of the circumstances existing at the time it is delivered to a purchaser, or if it
shall be necessary, in the opinion of such counsel, at any such time to amend the Registration
Statement or amend or supplement the Prospectus in order to comply
13
with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly
prepare and file with the Commission, subject to Section 3(b), such amendment or supplement as may
be necessary to correct such statement or omission or to make the Registration Statement or the
Prospectus comply with such requirements, and the Company will furnish to the Underwriters such
number of copies of such amendment or supplement as the Underwriters may reasonably request.
(f) Blue Sky Qualifications. The Company will use its commercially reasonable best efforts, in
cooperation with the Underwriters, to qualify the Securities for offering and sale under the
applicable securities laws of such states and other jurisdictions (domestic or foreign) as the
Representatives may designate and to maintain such qualifications in effect for a period of not
less than one year from the later of the effective date of the Registration Statement and any Rule
462(b) Registration Statement; provided, however, that the Company shall not be obligated to file
any general consent to service of process or to qualify as a foreign corporation or as a dealer in
securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in
respect of doing business in any jurisdiction in which it is not otherwise so subject.
(g) Rule 158. The Company will timely file such reports pursuant to the 1934 Act as are
necessary in order to make generally available to its securityholders as soon as practicable an
earnings statement for the purposes of, and to provide the benefits contemplated by the last
paragraph of Section 11(a) of the 1933 Act.
(h) Use of Proceeds. The Company will use the net proceeds received by it from the sale of the
Securities in the manner specified in the Prospectus under “Use of Proceeds.”
(i) Listing. The Company will use its commercially reasonable best efforts to effect and
maintain the listing of the Common Stock (including the Securities) on the American Stock Exchange.
(j) Restriction on Sale of Securities. During a period of 180 days from the date of the
Prospectus, the Company will not, without the prior written consent of GAF, (i) directly or
indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase or
otherwise transfer or dispose of any share of Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock or file any registration statement under the 1933 Act
with respect to any of the foregoing or (ii) enter into any swap or any other agreement or any
transaction that transfers, in whole or in part, directly or indirectly, the economic consequence
of ownership of the Common Stock, whether any such swap or transaction described in clause (i) or
(ii) above is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise. The foregoing sentence shall not apply to (A) the Securities to be sold hereunder, (B)
any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the
conversion of a security outstanding on the date hereof and referred to in the Prospectus, (C) any
shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing
employee benefit plans of the Company referred to in the Prospectus, (D) any shares of Common Stock
issued pursuant to the Company’s 401(k) plan referred to in the Prospectus, (E) any shares of
Common Stock of the Company in connection with acquisition or merger transactions approved by the
Company’s board of directors or (F) pledges of shares of Common Stock pursuant to bona fide loan
transactions, provided that in the case of clause (F) above, the proposed transferee agrees to be
bound by the first sentence of this Section.
(k) Reporting Requirements. The Company, during the period when the Prospectus is required to
be delivered under the 1933 Act, will file all documents required to be filed with the Commission
14
pursuant to the 1934 Act within the time periods required by the 1934 Act and the rules and
regulations of the Commission thereunder.
(l) Transfer Agent. The Company will maintain a transfer agent and, if necessary under the
jurisdiction of incorporation of the Company, a registrar for the Common Stock.
(m) Reserved Securities. The Company will comply with all applicable securities and other
applicable laws, rules and regulations in each jurisdiction in which the Reserved Securities are
offered.
SECTION 4. Payment of Expenses.
(a) Expenses. The Company will pay all expenses incident to the performance of its obligations
under this Agreement, including (i) the preparation, printing and filing of the Registration
Statement (including financial statements and exhibits) as originally filed and of each amendment
thereto, (ii) the preparation, printing and delivery to the Underwriters of this Agreement and such
other documents as may be required in connection with the offering, purchase, sale, issuance or
delivery of the Securities, including printing and delivering all closing documents and any
compilations thereof, (iii) the preparation, issuance and delivery of the certificates for the
Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other
duties payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv) the
fees and disbursements of the Company’s counsel, accountants and other advisors, (v) the
qualification of the Securities under securities laws in accordance with the provisions of Section
3(f) hereof, including filing fees and the reasonable fees and disbursements of counsel for the
Underwriters in connection therewith and in connection with the preparation of the Blue Sky Survey
and any supplement thereto, (vi) the printing and delivery to the Underwriters of copies of each
preliminary prospectus and of the Prospectus and any amendments or supplements thereto, (vii) the
preparation, printing and delivery to the Underwriters of copies of the Blue Sky Survey and any
supplement thereto, (viii) the fees and expenses of any transfer agent or registrar for the
Securities, (ix) the costs and expenses of the Company relating to investor presentations on any
“road show” undertaken in connection with the marketing of the Securities, including without
limitation, expenses associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged in connection with the road show presentations, travel and
lodging expenses of the Representatives and the Company and any such consultants, and the cost of
aircraft and other transportation chartered in connection with the road show , (x) the filing fees
incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection
with, the review by the National Association of Securities Dealers, Inc. (the “NASD”) of the terms
of the sale of the Securities, (xi) the fees and expenses incurred in connection with the listing
of the Securities on the American Stock Exchange, (xii) all costs and expenses of the Underwriters,
including the fees and disbursements of counsel for the Underwriters, in connection with matters
related to the Reserved Securities which are designated by the Company for sale to Invitees, and
(xiii) all expenses relating to the preparation and delivery of the Power of Attorney and Custody
Agreement and any other document relating to the sale of Securities by any Selling Shareholder.
(b) Expenses of the Selling Shareholder(s). The Selling Shareholders, severally but not
jointly, will pay all expenses incident to the performance of their respective obligations under,
and the consummation of the transactions contemplated by this Agreement, including (i) any stamp
duties, capital duties and stock transfer taxes, if any, payable upon the sale of the Securities to
the Underwriters, and (ii) the fees and disbursements of their respective counsel and other
advisors.
(c) Termination of Agreement. If this Agreement is terminated by the Representative(s) in
accordance with the provisions of Section 5, Section 9(a)(i) or Section 11 hereof, the Company and
the
15
Selling Shareholders shall reimburse the Underwriters for all of their reasonable
out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the
Underwriters.
(d) Allocation of Expenses. The provisions of this Section shall not affect any agreement
that the Company and the Selling Shareholders may make for the sharing of such costs and expenses.
SECTION 5. Conditions of Underwriters’ Obligations. The obligations of the several
Underwriters hereunder are subject to the accuracy of the representations and warranties of the
Company and the Selling Shareholders contained in Section 1 hereof or in certificates of any
officer of the Company or any subsidiary of the Company or on behalf of any Selling Shareholder
delivered pursuant to the provisions hereof, to the performance by the Company and the Selling
Shareholders of their covenants and other obligations hereunder, and to the following further
conditions:
(a) Effectiveness of Registration Statement. The Registration Statement, including any Rule
462(b) Registration Statement, has become effective and at Closing Time no stop order suspending
the effectiveness of the Registration Statement shall have been issued under the 1933 Act or
proceedings therefor initiated or threatened by the Commission, and any request on the part of the
Commission for additional information shall have been complied with to the reasonable satisfaction
of counsel to the Underwriters. A prospectus containing the Rule 430A Information shall have been
filed with the Commission in accordance with Rule 424(b) (or a post-effective amendment providing
such information shall have been filed and declared effective in accordance with the requirements
of Rule 430A).
(b) Opinion of Counsel for Company. At Closing Time, the Representatives shall have received
the favorable opinion, dated as of Closing Time, of Akerman Senterfitt, counsel for the Company, in
form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced
copies of such letter for each of the other Underwriters to the effect set forth in Exhibit A
hereto and to such further effect as counsel to the Underwriters may reasonably request.
(c) Opinion of Counsel for Underwriters. At Closing Time, the Representatives shall have
received the favorable opinion, dated as of Closing Time, of Xxxxx & Xxxxxxx LLP, counsel for the
Underwriters, together with signed or reproduced copies of such letter for each of the other
Underwriters with respect to the issuance and sale of the Securities, the Registration Statement,
the Prospectus (together with any amendment or supplement thereto) and other related matters as the
Representatives may reasonably request and the Company shall have furnished to such counsel such
documents as they request for the purpose of enabling them to opine upon such matters.
(d) Officers’ Certificate. At Closing Time, there shall not have been, since the date hereof
or since the respective dates as of which information is given in the Prospectus, any material
adverse change in the condition, financial or otherwise, or in the earnings, business affairs or
business prospects of the Company and its subsidiaries considered as one enterprise, whether or not
arising in the ordinary course of business, and the Representatives shall have received a
certificate of the President or a Vice President of the Company and of the chief financial or chief
accounting officer of the Company, dated as of Closing Time, to the effect that (i) there has been
no such material adverse change, (ii) the representations and warranties in Section l(a) hereof are
true and correct with the same force and effect as though expressly made at and as of Closing Time,
(iii) the Company has complied with all agreements and satisfied all conditions on its part to be
performed or satisfied at or prior to Closing Time, and (iv) no stop order suspending the
effectiveness of the Registration Statement has been issued and no proceedings for that purpose
have been instituted or are pending or, to their knowledge, contemplated by the Commission.
(e) Accountant’s Comfort Letter. At the time of the execution of this Agreement, the
Representatives shall have received from Xxxxxxxxx & Associates, P.A. a letter dated such date, in
form
16
and substance satisfactory to the Representatives, together with signed or reproduced copies
of such letter for each of the other Underwriters containing statements and information of the type
ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial
statements and certain financial information contained in the Registration Statement and the
Prospectus.
(f) Bring-down Comfort Letter. At Closing Time, the Representatives shall have received from
Xxxxxxxxx & Associates, P.A. a letter, dated as of Closing Time, to the effect that they reaffirm
the statements made in the letter furnished pursuant to subsection (e) of this Section, except that
the specified date referred to shall be a date not more than three business days prior to Closing
Time.
(g) Approval of Listing. At Closing Time, the Securities shall have been approved for listing
on the American Stock Exchange, subject only to official notice of issuance.
(h) No Objection. The NASD has confirmed that it has not raised any objection with respect to
the fairness and reasonableness of the underwriting terms and arrangements.
(i) Lock-up Agreements. At the date of this Agreement, the Representatives shall have received
an agreement substantially in the form of Exhibit B hereto signed by the persons listed on Schedule
D hereto.
(j) Warrant. At the Closing Time, the Representatives shall each have received a Warrant
substantially in the form of Exhibit C signed by the Company
(k) Conditions to Purchase of Option Securities. In the event that the Underwriters exercise
their option provided in Section 2(b) hereof to purchase all or any portion of the Option
Securities, the representations and warranties of the Company contained herein and the statements
in any certificates furnished by the Company or any subsidiary of the Company hereunder shall be
true and correct as of the Date of Delivery and, at the Date of Delivery, the Representatives shall
have received:
i. Officers’ Certificate. A certificate, dated the Date of Delivery, of the
President or a Vice President of the Company and of the chief financial or chief accounting
officer of the Company confirming that the certificate delivered at the Closing Time
pursuant to Section 5(d) hereof remains true and correct as of the Date of Delivery.
ii. Certificate of Selling Shareholders. A certificate of an Attorney-in-Fact
on behalf of each Selling Shareholder, dated the Date of Delivery, to the effect that (i)
the representations and warranties of each Selling Shareholder contained in Section 1(b)
hereof are true and correct in all respects with the same force and effect as though
expressly made at and as of the Date of Delivery and (ii) each Selling Shareholder has
complied in all material respects with all agreements and all conditions on its part to be
performed under this Agreement at or prior to the Date of Delivery.
iii. Opinion of Counsel for Company. The favorable opinion of Akerman
Senterfitt, counsel for the Company, in form and substance satisfactory to counsel for the
Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased
on the Date of Delivery and otherwise to the same effect as the opinion required by Section
5(b) hereof.
iv. Opinion of Counsel for Underwriters. The favorable opinion of Xxxxx &
Xxxxxxx LLP, counsel for the Underwriters, dated the Date of Delivery, relating to the
Option Securities to be purchased on the Date of Delivery and otherwise to the same effect
as the opinion required by Section 5(c) hereof.
17
v. Opinion of Counsel for the Selling Shareholders. The favorable opinion,
dated the Date of Delivery, of Akerman Senterfitt, counsel for the Selling Shareholders, in
form and substance satisfactory to counsel for the Underwriters, together with signed or
reproduced copies of such letter for each of the other Underwriters to the effect set forth
in Exhibit A hereto and to such further effect as counsel to the Underwriters may reasonably
request.
vi. Bring-down Comfort Letter. A letter from Xxxxxxxxx & Associates, P.A., in
form and substance satisfactory to the Representatives and dated the Date of Delivery,
substantially in the same form and substance as the letter furnished to the Representatives
pursuant to Section 5(f) hereof, except that the “specified date” in the letter furnished
pursuant to this paragraph shall be a date not more than five days prior to the Date of
Delivery.
(l) Additional Documents. At Closing Time and at each Date of Delivery, counsel for the
Underwriters shall have been furnished with such documents and opinions as they may reasonably
require for the purpose of enabling them to pass upon the issuance and sale of the Securities as
herein contemplated, or in order to evidence the accuracy of any of the representations or
warranties, or the fulfillment of any of the conditions, herein contained, and all proceedings
taken by the Company in connection with the issuance and sale of the Securities as herein
contemplated shall be satisfactory in form and substance to the Representatives and counsel for the
Underwriters.
(m) Termination of Agreement. If any condition specified in this Section shall not have been
fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to
the purchase of Option Securities, on the Date of Delivery which is after the Closing Time, the
obligations of the several Underwriters to purchase the relevant Option Securities, may be
terminated by the Representatives by notice to the Company at any time at or prior to Closing Time
or the Date of Delivery, as the case may be, and such termination shall be without liability of any
party to any other party except as provided in Section 4 and except that Sections 1, 6, 7 and 8
shall survive any such termination and remain in full force and effect.
SECTION 6. Indemnification.
(a) Indemnification of Underwriters. The Company agrees to indemnify and hold harmless each
Underwriter, its affiliates, as such term is defined in Rule 501(b) under the 1933 Act (each, an
“Affiliate”), its selling agents and each person, if any, who controls any Underwriter within the
meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows:
i. against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, arising out of any untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement (or any amendment thereto), including the Rule 430A
Information or the omission or alleged omission therefrom of a material fact required to be
stated therein or necessary to make the statements therein not misleading or arising out of
any untrue statement or alleged untrue statement of a material fact included in any
preliminary prospectus or the Prospectus (or any amendment or supplement thereto), or the
omission or alleged omission therefrom of a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not
misleading;
ii. against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or
of any claim whatsoever based upon any such untrue statement or omission, or my such alleged
18
untrue statement or omission; provided that (subject to Section 6(e) below) any such
settlement is effected with the written consent of the Company;
iii. against any and all expense whatsoever, as incurred (including the fees and
disbursements of counsel chosen by GAF), reasonably incurred in investigating, preparing or
defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue
statement or omission, or any such alleged untrue statement or omission, to the extent that
any such expense is not paid under (i) or (ii) above;
provided, however, that this indemnity agreement shall not apply to any loss,
liability, claim, damage or expense to the extent arising out of any untrue statement or omission
or alleged untrue statement or omission made in reliance upon and in conformity with written
information furnished to the Company by any Underwriter expressly for use in the Registration
Statement (or any amendment thereto), including the Rule 430A Information or any preliminary
prospectus or the Prospectus (or any amendment or supplement thereto).
(b) The Selling Shareholders, severally but not jointly, agree to indemnify and hold harmless
each Underwriter, its Affiliates and selling agents and each person, if any, who controls any
Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act to the
extent and in the manner set forth in clauses, (a)(i), (ii) and (iii) above and in Section 6(e).
(c) Indemnification of Company, Directors and Officers and Selling Shareholders. Each
Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its
officers who signed the Registration Statement, and each person, if any, who controls the Company
within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Selling
Shareholder against any and all loss, liability, claim, damage and expense described in the
indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue
statements or omissions, or alleged untrue statements or omissions, made in the Registration
Statement (or any amendment thereto), including the Rule 430A Information or any preliminary
prospectus or the Prospectus (or any amendment or supplement thereto) in reliance upon and in
conformity with written information furnished to the Company by such Underwriter expressly for use
in the Registration Statement (or any amendment thereto) or such preliminary prospectus or the
Prospectus (or any amendment or supplement thereto).
(d) Actions against Parties; Notification. Each indemnified party shall give notice as
promptly as reasonably practicable to each indemnifying party of any action commenced against it in
respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party
shall not relieve such indemnifying party from any liability hereunder to the extent it is not
materially prejudiced as a result thereof and in any event shall not relieve it from any liability
which it may have otherwise than on account of this indemnity agreement. In the case of parties
indemnified pursuant to Section 6(a) or (b) above, counsel to the indemnified parties shall be
selected by GAF, and, in the case of parties indemnified pursuant to Section 6(c) above, counsel to
the indemnified parties shall be selected by the Company. An indemnifying party may participate at
its own expense in the defense of any such action; provided, however, that counsel to the
indemnifying party shall not (except with the consent of the indemnified party) also be counsel to
the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses
of more than one counsel (in addition to any local counsel) separate from their own counsel for all
indemnified parties in connection with any one action or separate but similar or related actions in
the same jurisdiction arising out of the same general allegations or circumstances. No
indemnifying party shall, without the prior written consent of the indemnified parties, settle or
19
compromise or consent to the entry of any judgment with respect to any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or any
claim whatsoever in respect of which indemnification or contribution could be sought under this
Section 6 or Section 7 hereof (whether or not the indemnified parties are actual or potential
parties thereto), unless such settlement, compromise or consent (i) includes an unconditional
release of each indemnified party from all liability arising out of such litigation, investigation,
proceeding or claim and (ii) does not include a statement as to or an admission of fault,
culpability or a failure to act by or on behalf of any indemnified party.
(e) Settlement without Consent if Failure to Reimburse. If at any time an indemnified party
shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses
of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated by Section 6(a)(ii) or settlement of any claim in connection with any violation
referred to in Section 6(f) effected without its written consent if (i) such settlement is entered
into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such
indemnifying party shall have received notice of the terms of such settlement at least 30 days
prior to such settlement being entered into and (iii) such indemnifying party shall not have
reimbursed such indemnified party in accordance with such request prior to the date of such
settlement.
(f) Indemnification for Reserved Securities. In connection with the offer and sale of the
Reserved Securities, the Company agrees, to indemnify and hold harmless the Underwriters, their
Affiliates and selling agents and each person, if any, who controls any Underwriter within the
meaning of either Section 15 of the 1933 Act or Section 20 of the 1934 Act, from and against any
and all loss, liability, claim, damage and expense (including, without limitation, any legal or
other expenses reasonably incurred in connection with defending, investigating or settling any such
action or claim), as incurred, (i) arising out of the violation of any applicable laws or
regulations of foreign jurisdictions where Reserved Securities have been offered; (ii) arising out
of any untrue statement or alleged untrue statement of a material fact contained in any prospectus
wrapper or other material prepared by or with the consent of the Company for distribution to
Invitees in connection with the offering of the Reserved Securities or caused by any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading; (iii) caused by the failure of any Invitee to pay for
and accept delivery of Reserved Securities which have been orally confirmed for purchase by any
Invitee by the end of the first business day after the date of the Agreement; or (iv) related to,
or arising out of or in connection with, the offering of the Reserved Securities.
SECTION 7. Contribution. If the indemnification provided for in Section 6 hereof is
for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of
any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and
expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate
to reflect the relative benefits received by the Company, each Selling Shareholder, and the
Underwriters from the offering of the Securities pursuant to this Agreement or (ii) if the
allocation provided by clause (i) is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause (i) above but also the
relative fault of the Company on the one hand and of the Underwriters on the other hand in
connection with the statements or omissions, or in connection with any violation of the nature
referred to in Section 6(f) hereof, which resulted in such losses, liabilities, claims, damages or
expenses, as well as any other relevant equitable considerations.
The relative benefits received by the Company, each Selling Shareholder, and the Underwriters
in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be
in the same respective proportions as the total net proceeds from the offering of the Securities
pursuant to this
20
Agreement (before deducting expenses) received by the Company and each Selling Shareholder and
the total underwriting discount received by the Underwriters, in each case as set forth on the
cover of the Prospectus, bear to the aggregate initial public offering price of the Securities as
set forth on the cover of the Prospectus.
The relative fault of the Company, each Selling Shareholder and the Underwriters shall be
determined by reference to, among other things, whether any such untrue or alleged untrue statement
of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission or any violation of
the nature referred to in Section 6(f) hereof.
The Company, each Selling Shareholder, and the Underwriters agree that it would not be just
and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation
(even if the Underwriters were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to above in this
Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an
indemnified party and referred to above in this Section 7 shall be deemed to include any legal or
other expenses reasonably incurred by such indemnified party in investigating, preparing or
defending against any litigation, or any investigation or proceeding by any governmental agency or
body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue
statement or omission or alleged omission.
Notwithstanding the provisions of this Section 7, no Underwriter shall be required to
contribute any amount in excess of the amount by which the total price at which the Securities
underwritten by it and distributed to the public were offered to the public exceeds the amount of
any damages which such Underwriter has otherwise been required to pay by reason of any such untrue
or alleged untrue statement or omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
0000 Xxx) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.
For purposes of this Section 7, each person, if any, who controls an Underwriter within the
meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Underwriter’s
Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and
each director of the Company, each officer of the Company who signed the Registration Statement,
and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act
or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The
Underwriters’ respective obligations to contribute pursuant to this Section 7 are several in
proportion to the number of Initial Securities set forth opposite their respective names in
Schedule A hereto and not joint.
SECTION 8. Representations, Warranties and Agreements to Survive. All representations,
warranties and agreements contained in this Agreement or in certificates of officers of the Company
or any of its subsidiaries or the Selling Shareholders submitted pursuant hereto, shall remain
operative and in full force and effect regardless of (i) any investigation made by or on behalf of
any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its
officers or directors or any person controlling the Company and (ii) delivery of and payment for
the Securities.
21
SECTION 9. Termination of Agreement.
(a) Termination; General. The Representatives may terminate this Agreement, by notice to the
Company, at any time at or prior to Closing Time (i) if there has been, since the time of execution
of this Agreement or since the respective dates as of which information is given in the Prospectus,
any material adverse change in the condition, financial or otherwise, or in the earnings, business
affairs or business prospects of the Company and its subsidiaries considered as one enterprise,
whether or not arising in the ordinary course of business, which would, in GAF’s judgment or in the
judgment of such group of Underwriters, make it impracticable or inadvisable to proceed with the
public offering or the delivery of the Securities, or (ii) if there has occurred any material
adverse change in the financial markets in the United States or the international financial
markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any
change or development involving a prospective change in national or international political,
financial or economic conditions, in each case the effect of which is such as to make it, in the
judgment of the Representatives, impracticable or inadvisable to market the Securities or to
enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the
Company has been suspended or materially limited by the Commission or the American Stock Exchange,
or if trading generally on the American Stock Exchange or the New York Stock Exchange or in the
Nasdaq National Market has been suspended or materially limited, or minimum or maximum prices for
trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges
or by such system or by order of the Commission, the National Association of Securities Dealers,
Inc. or any other governmental authority, or (iv) a material disruption has occurred in commercial
banking or securities settlement or clearance services in the United States, or (v) if a banking
moratorium has been declared by either Federal, New York or Florida authorities.
(b) Liabilities. If this Agreement is terminated pursuant to this Section, such termination
shall be without liability of any party to any other party except as provided in Section 4 hereof,
and provided further that Sections 1, 6, 7 and 8 shall survive such termination and remain in full
force and effect.
SECTION 10. Default by One or More of the Underwriters. If one or more of the
Underwriters shall fail at Closing Time or the Date of Delivery to purchase the Securities which it
or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the
Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or
more of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less
than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms
herein set forth, if, however, the Representatives shall not have completed such arrangements
within such 24-hour period, then:
i. if the number of Defaulted Securities does not exceed 10% of the number of
Securities to be purchased on such date, each of the non-defaulting Underwriters shall be
obligated, severally and not jointly, to purchase the full amount thereof in the proportions
that their respective underwriting obligations hereunder bear to the underwriting
obligations of non-defaulting Underwriters, or
ii. if the number of Defaulted Securities exceeds 10% of the number of Securities to be
purchased on such date, this Agreement or, with respect to the Date of Delivery which occurs
after the Closing Time, the obligation of the Underwriters to purchase and of the Company to
sell the Option Securities to be purchased and sold on the Date of Delivery shall terminate
without liability on the part of any non-defaulting Underwriter.
No action taken pursuant to this Section shall relieve any defaulting Underwriter from
liability in respect of its default.
22
In the event of any such default which does not result in a termination of this Agreement or,
in the case of the Date of Delivery which is after the Closing Time, which does not result in a
termination of the obligation of the Underwriters to purchase and the Selling Shareholders to sell
the Option Securities, as the case may be, either the Representatives or the Company or the
Attorney-in-Fact for the Selling Shareholders, as the case may be, shall have the right to postpone
Closing Time or the Date of Delivery, as the case may be, for a period not exceeding seven days in
order to effect any required changes in the Registration Statement or Prospectus or in any other
documents or arrangements. As used herein, the term “Underwriter” includes any person substituted
for an Underwriter under this Section 10.
SECTION 11. Default by One or More of the Selling Shareholders. If a Selling
Shareholder shall fail at the Date of Delivery to sell and deliver the number of Securities which
such Selling Shareholder is obligated to sell hereunder, and the remaining Selling Shareholders do
not exercise the right hereby granted to increase, pro rata or otherwise, the number of Securities
to be sold by them hereunder to the total number to be sold by all Selling Shareholders as set
forth in Schedule B hereto, then the Underwriters may, at the option of the Representatives, by
notice from the Representatives to the non-defaulting Selling Shareholders, either (i) terminate
this Agreement without any liability on the fault of any non-defaulting party except that the
provisions of Sections 1, 4, 6, 7 and 8 shall remain in full force and effect or (ii) elect to
purchase the Securities which the non-defaulting Selling Shareholders have agreed to sell
hereunder. No action taken pursuant to this Section 11 shall relieve any Selling Shareholder so
defaulting from liability, if any, in respect of such default.
In the event of a default by any Selling Shareholder as referred to in this Section 11, each
of the Representatives and the non-defaulting Selling Shareholders shall have the right to postpone
the Date of Delivery for a period not exceeding seven days in order to effect any required change
in the Registration Statement or Prospectus or in any other documents or arrangements.
SECTION 12. Tax Disclosure. Notwithstanding any other provision of this Agreement,
immediately upon commencement of discussions with respect to the transactions contemplated hereby,
the Company (and each employee, representative or other agent of the Company) may disclose to any
and all persons, without limitation of any kind, the tax treatment and tax structure of the
transactions contemplated by this Agreement and all materials of any kind (including opinions or
other tax analyses) that are provided to the Company relating to such tax treatment and tax
structure, For purposes of the foregoing, the term “tax treatment” is the purported or claimed
federal income tax treatment of the transactions contemplated hereby.
SECTION 13. Notices. All notices and other communications hereunder shall be in
writing and shall be deemed to have been duly given if mailed or transmitted by any standard form
of telecommunication. Notices to the Underwriters shall be directed to the Representatives c/o
GunnAllen Financial, Inc., 0000 Xxxx Xxxxxx Xxxxxx, Xxxxx, Xxxxxxx 00000, attention of Xxxxx Xxxxx
and notices to the Company shall be directed to it at 0000 XX 0xx Xxxxxx, Xxxxx 000, Xx.
Xxxxxxxxxx, Xxxxxxx 00000, attention of Xxxx X. Xxxxxx, and notices to the Selling Shareholders
shall be directed to Xxxxxx Xxxxxxx at the address for the Company listed above.
SECTION 14. Parties. This Agreement shall each inure to the benefit of and be binding
upon the Underwriters, the Company and the Selling Shareholders and their respective successors.
Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any
person, firm or corporation, other than the Underwriters, the Company and the Selling Shareholders
and their respective successors and the controlling persons and officers and directors referred to
in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy
or claim under or in respect of this Agreement or any provision herein contained. This Agreement
and all conditions and provisions hereof
23
are intended to be for the sole and exclusive benefit of the Underwriters, the Company and the
Selling Shareholders and their respective successors, and said controlling persons and officers and
directors and their heirs and legal representatives, and for the benefit of no other person, firm
or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor
by reason merely of such purchase.
SECTION 15. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.
SECTION 16. TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE
SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
SECTION 17. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall
together constitute one and the same Agreement.
SECTION 18. Effect of Headings. The Section headings herein are for convenience only
and shall not affect the construction hereof.
24
If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company and the Attorney-in-Fact for the Selling Shareholders a counterpart hereof,
whereupon this instrument, along with all counterparts, will become a binding agreement between the
Underwriters, the Company and the Selling Shareholders in accordance with its terms.
Very truly yours, Baby Universe, Inc. |
||||
By: | /s/ | |||
Title: | ||||
[Name of Attorney-in-Fact] |
||||
By: | /s/ | |||
As Attorney-in-Fact acting on behalf of the | ||||
Selling Shareholders named in Schedule B hereto | ||||
CONFIRMED AND ACCEPTED,
As of the date first above written:
As of the date first above written:
GUNNALLEN FINANCIAL, INC.
WEDBUSH XXXXXX SECURITIES
By: GUNNALLEN FINANCIAL, INC.
By: | Authorized Signatory |
For themselves and as Representatives of the other Underwriters named in Schedule A hereto.
25
SCHEDULE A
Number of | ||||
Name of Underwriter | Initial Securities | |||
GunnAllen Financial, Inc. |
||||
Wedbush Xxxxxx Securities |
||||
Total |
2,000,000 | |||
Sch A-1
Schedule B
Maximum Number of Option | ||||
Securities to Be Sold | ||||
Wyndcrest Baby Universe Holdings, LLC |
86,196 | |||
Wyndcrest Baby Universe Holdings II, LLC |
186,269 | |||
Wyndcrest Baby Universe Holdings III, LLC |
5,154 | |||
Xxxxxxxx Xxxxx |
5,244 | |||
Xxxx Xxxxx |
17,137 | |||
Total |
300,000 | |||
Sch B-1
Schedule C
Baby Universe, Inc.
2,000,000 Shares of Common Stock
(Par Value $.001 Per Share)
Baby Universe, Inc.
2,000,000 Shares of Common Stock
(Par Value $.001 Per Share)
1. The initial public offering price per share for the Securities, determined as provided in
Section 2, shall be $•.
2. The purchase price per share for the Securities to be paid by the several Underwriters
shall be $•, being an amount equal to the initial public offering price set forth above less $• per
share; provided that the purchase price per share for any Option Securities purchased upon the
exercise of the overallotment option described in Section 2(b) shall be reduced by an amount per
share equal to any dividends or distributions declared by the Company and payable on the Initial
Securities but not payable on the Option Securities.
Sch C-1
Schedule D
Xxxx X. Xxxxxx
Xxxxxx Xxxxxxx
Xxxxxxxx Xxxxxxx
Xxxxxx Xxxxx
Xxxxxxxxxx Xxxxx
Xxxx Xxxxx
Xxxxxx X. Xxxxxx
Xxxxxx X. Xxxxxxxx
Xxxx Xxxxxxx
Xxxx Xxxxx
Wyndcrest Baby Universe Holdings, LLC
Wyndcrest Baby Universe Holdings II, LLC
Wyndcrest Baby Universe Holdings III, LLC
Sch D-1
Exhibit A
FORM OF OPINION OF COMPANY’S COUNSEL
TO BE DELIVERED PURSUANT TO SECTION 5(b)
TO BE DELIVERED PURSUANT TO SECTION 5(b)
1. The Company is a corporation duly incorporated under the laws of the State of Florida, with
corporate power and authority to own, lease and operate its properties and to conduct its business
as described in the Prospectus and to enter into and perform its obligations under the Underwriting
Agreement.
2. The Company is validly existing and has an active status under the laws of the State of
Florida and is qualified to do business in each jurisdiction in which such qualification is
required, whether by reason of the ownership or leasing of property or the conduct of business,
except where the failure to so qualify or be in good standing would not result in a Material
Adverse Effect.
3. Each subsidiary of the Company listed in Exhibit 21 of the Registration Statement (each
being referred to as a “Subsidiary”) is a corporation, duly incorporated or organized under the
laws of the state of its incorporation or organization, with power and authority (corporate or
other) to own, lease and operate its properties and to conduct its business as described in the
Prospectus. Each Subsidiary of the Company is validly existing and in good standing under the laws
of the state of its incorporation or organization and in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of property or the conduct
of business, except where the failure to so qualify or be in good standing would not result in a
Material Adverse Effect.
4. All of the issued and outstanding capital stock or other equity or ownership interests of
each Subsidiary of the Company have been duly authorized and validly issued, are fully paid and
non-assessable and, based upon a review within five days prior to the date hereof of certificates
representing outstanding capital stock or other equity or ownership interests of, and stock,
ownership or other equity transfer records for, such Subsidiaries, all of the outstanding shares of
capital stock or other equity or ownership interests of such Subsidiaries were owned of record on
that date by the Company, directly or through subsidiaries, and, to our knowledge, free and clear
of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. To our knowledge,
none of the outstanding shares of capital stock of any subsidiary was issued in violation of the
preemptive or similar rights of any security holder of such Subsidiary.
5. The authorized, issued and outstanding capital stock of the Company (including the
Securities) conforms to the descriptions thereof set forth in the Prospectus. The authorized,
issued and outstanding capital stock of the Company is as set forth in the Prospectus in the column
entitled “Actual” under the caption “Capitalization” (except for subsequent issuances, if any,
pursuant to the Underwriting Agreement or pursuant to reservations, agreements or employee benefit
plans referred to in the Prospectus or pursuant to the exercise of convertible securities or
options referred to in the Prospectus); the shares of issued and outstanding capital stock of the
Company, including the Securities to be purchased by the Underwriters from the Selling
Shareholders, are validly issued and are fully paid and non-assessable; and, to our knowledge, none
of the outstanding shares of capital stock of the Company was issued in violation of the preemptive
or other similar rights of any securityholder of the Company. The form of certificate used to
evidence the Securities is in due and proper form and complies with all applicable statutory
requirements, and the charter and by-laws of the Company, and the requirements of the American
Stock Exchange.
A-1
6. No shareholder of the Company or any other person has any preemptive right, right of first
refusal or other similar right to subscribe for or purchase securities of the Company arising by
operation of the charter or by-laws of the Company or the Florida Business Corporation Act or to
our knowledge, otherwise.
7. To our knowledge and except as described in the Registration Statement, no shareholder of
the Company or any other person has any contractual right to have any Common Stock or other
securities of the Company included in the Registration Statement
8. The Underwriting Agreement has been duly authorized, executed and delivered by the Company.
9. The Securities to be purchased by the Underwriters from the Company have been duly
authorized for issuance and sale pursuant to the Underwriting Agreement and, when issued and
delivered by the Company pursuant to the Underwriting Agreement against payment of the
consideration set forth therein, will be validly issued, fully paid and nonassessable.
10. Each of the Registration Statement and the Rule 462(b) Registration Statement, if any, has
been declared effective by the Commission under the 1933 Act. To our knowledge, no stop order
suspending the effectiveness of either of the Registration Statement or the Rule 462(b)
Registration Statement, if any, has been issued under the 1933 Act and no proceedings for such
purpose have been instituted or are pending or are contemplated or threatened by the Commission.
Any required filing of the Prospectus and any supplement thereto pursuant to Rule 424(b) under the
1933 Act has been made in the manner and within the time period required by such Rule 424(b).
11. The Registration Statement, including any Rule 462(b) Registration Statement, the
Prospectus, and each amendment or supplement to the Registration Statement and the Prospectus, as
of their respective effective or issue dates (other than the financial statements and supporting
schedules included therein, as to which no opinion need be rendered) complied as to form in all
material respects with the applicable requirements of the 1933 Act and the 1933 Act Regulations.
12. Based on written advice from the American Stock Exchange, the securities have been
approved for listing on the American Stock Exchange.
13. The statements in the Prospectus under the captions “Risk Factors,” “Business –
Intellectual Property,” “Business-Government Regulation,” “Description of Capital Stock,” “Shares
Eligible for Future Sale,” “Certain Relationships and Related Transactions,” and in the
Registration Statement under Item 14, insofar as such statements constitute matters of law,
summaries of legal matters, or legal conclusions are accurate in all material respects.
14. To our knowledge, there are no legal or governmental actions, suits or proceedings pending
or threatened that are required to be disclosed in the Registration Statement, other than those
disclosed therein.
15. To our knowledge, there are no franchises, contracts, indentures, mortgages, loan
agreements, notes, leases or other instruments required to be described or referred to in the
Registration Statement or to be filed as exhibits thereto other than those described or referred to
therein or filed as exhibits thereto; and the descriptions thereof and references thereto are
accurate in all material respects.
16. The execution and delivery of the Underwriting Agreement by the Company, the performance
by the Company of its obligations thereunder (other than performance by the Company of its
A-2
obligations under the indemnification section of the Underwriting Agreement, as to which no
opinion need be rendered) and the issuance and sale of the Securities and the use of proceeds from
the sale of Securities as described in the Prospectus under the caption “Use of Proceeds” (i) have
been duly authorized by all necessary corporate action on the part of the Company; (ii) will not
result in any violation of the provisions of the charter or by-laws of the Company or any
Subsidiary; (iii) will not conflict with or constitute a breach of, or default under or Repayment
Event, or result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company or any of its subsidiaries pursuant to any contract, indenture, mortgage,
deed of trust, loan or credit agreement, note, lease or any other agreement or instrument known to
us; (iv) will not result in any violation of any federal or Florida law or, to our knowledge any
administrative regulation or administrative or court decree applicable to the Company; or (v) will
not require any consents, approvals or authorizations to be obtained by the Company, or any
registrations, declarations or filings to be made by the Company, in each case, under any federal
or Florida statute, or rule or regulation applicable to the Company that have not been obtained or
made.
17. The Company is not, and after receipt of payment for the Securities will not be, an
“investment company” within the meaning of Investment Company Act.
During the course of the preparation of the Registration Statement, we participated in
conferences with officers and other representatives of the Company, representatives of the
Underwriters and representatives of the Company’s certified public accountants, at which
conferences, the contents of the Registration Statement were discussed. On the basis of the
foregoing, during the course of the preparation of the Registration Statement and Prospectus (and
any amendment or supplement thereto), nothing has come to our attention that would lead us to
believe that (i) the Registration Statement or any amendment thereto (except for financial
statements and related notes and schedules thereto and other financial data included therein or
omitted therefrom, as to which we make no statement), at the time such Registration Statement or
any such amendment became effective, contained an untrue statement of a material fact or omitted to
state a material fact required to be stated therein or necessary to make the statements therein not
misleading or that (ii) the Prospectus or any amendment or supplement thereto (except for financial
statements and related notes and schedules thereto and other financial data included therein or
omitted therefrom, as to which we need make no statement), at the time the Prospectus was issued,
at the time any such amended or supplemented prospectus was issued or at the Closing, included or
includes an untrue statement of a material fact or omitted or omits to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading.
A-3
FORM OF OPINION OF COUNSEL FOR THE SELLING SHAREHOLDERS
TO BE DELIVERED PURSUANT TO SECTION 5(c)
TO BE DELIVERED PURSUANT TO SECTION 5(c)
(i) Each Power of Attorney and Custody Agreement has been duly authorized, executed and
delivered by the respective Selling Shareholder named therein and constitutes the valid and binding
agreement of such Selling Shareholder.
(ii) The Underwriting Agreement has been duly authorized, executed and delivered by or on
behalf of each Selling Shareholder and constitutes the valid and binding agreement of each Selling
Shareholder.
(iii) Each Attorney-in-Fact has been duly authorized by the Selling Shareholder to deliver the
Securities on behalf of each such Selling Shareholder in accordance with the terms of the
Underwriting Agreement.
(iv) The execution, delivery and performance of the Underwriting Agreement and the Power of
Attorney and Custody Agreement by the Selling Shareholders have been duly authorized by all
necessary action on the part of the Selling Shareholders and do not and will not, whether with or
without the giving of notice or passage of time or both, conflict with or constitute a breach of,
or default under or result in the creation or imposition of any tax, lien, charge or encumbrance
upon the Securities or any property or assets of the Selling Shareholders pursuant to, any
contract, indenture, mortgage, deed of trust, loan or credit agreement, note, license, lease or
other instrument or agreement known to us to which any Selling Shareholder is a party or by which
any Selling Shareholder may be bound, or to which any of the property or assets of the Selling
Shareholders may be subject nor will such action result in any violation of the provisions of the
charter, by-laws or any organizational documents of the Selling Shareholders, if applicable, or to
our knowledge any law, administrative regulation, judgment or order of any governmental agency or
body or any administrative or court decree having jurisdiction over any such Selling Shareholder or
any of their properties.
(v) To our knowledge, each of the Selling Shareholders has valid title to, or a valid security
entitlement in respect of, the Securities to be sold by such Selling Shareholder free and clear of
all security interests, claims, liens, equities and other encumbrances. Each of the Selling
Shareholders has the legal right and power, and all authorization and approval required by law, to
enter into the Underwriting Agreement and the Power of Attorney and Custody Agreement of such
Selling Shareholder and to sell, transfer and deliver the Securities to be sold by such Selling
Shareholder.
(vi) Upon the Underwriters’ acquiring possession of stock certificates representing the
Securities to be sold by the Selling Shareholders, endorsed to the Underwriters and paying the
purchase price therefor pursuant to the Underwriting Agreement, the Underwriters (assuming that no
such Underwriter has notice of any “adverse claim”, within the meaning of Chapter 678.1051 of the
Uniform Commercial Code as in effect in the State of Florida (“UCC”), as to such Securities) will
acquire their respective interests in such Securities (including, without limitation, all rights
that such Selling Shareholder had or has the power to transfer in such Securities) free and clear
of any adverse claim within the meaning of Chapter 678.1021 of the UCC.
A-4
Exhibit B
Lock-Up Agreement
GunnAllen Financial, Inc.
As Representative of the several
Underwriters named in Schedule I
to the Underwriting Agreement,
c/o GunnAllen Financial, Inc.
5000 Xxxx Xxxxxx Xxxxxx
Xxxxx, Xxxxxxx 00000
As Representative of the several
Underwriters named in Schedule I
to the Underwriting Agreement,
c/o GunnAllen Financial, Inc.
5000 Xxxx Xxxxxx Xxxxxx
Xxxxx, Xxxxxxx 00000
Re: Baby Universe, Inc. — Lock-Up Agreement
Ladies and Gentlemen:
The undersigned understands that you, as representative (the “Representative”), propose to
enter into an Underwriting Agreement on behalf of the several Underwriters named in Schedule I to
such agreement (collectively, the “Underwriters”), with Baby Universe, Inc., a Florida corporation
(the “Company”), providing for a public offering (the “Public Offering”) of the Common Stock of the
Company (the “Shares”) pursuant to a Registration Statement on Form S-1 to be filed with the
Securities and Exchange Commission (the “SEC”).
In consideration of the agreement by the Underwriters to offer and sell the Shares, and of
other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged,
the undersigned agrees that, during the period beginning from the date hereof and continuing to and
including the day that is 180 days after the closing of the Public Offering, the undersigned will
not offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or
otherwise dispose of any shares of Common Stock of the Company, or any options or warrants to
purchase any shares of Common Stock of the Company, or any securities convertible into,
exchangeable for or that represent the right to receive shares of Common Stock of the Company owned
directly by the undersigned (including holding as a custodian) or with respect to which the
undersigned has beneficial ownership within the rules and regulations of the SEC (collectively the
“Undersigned’s Shares”).
The foregoing restriction is expressly agreed to preclude the undersigned from engaging in any
hedging or other transaction that is designed to or that reasonably could be expected to lead to or
result in a sale or disposition of the Undersigned’s Shares even if such Shares would be disposed
of by someone other than the undersigned. Such prohibited hedging or other transactions would
include without limitation any short sale or any purchase, sale or grant of any right (including
without limitation any put or call option) with respect to any of the Undersigned’s Shares or with
respect to any security that includes, relates to, or derives any significant part of its value
from such Shares.
Notwithstanding the foregoing, the undersigned may transfer the Undersigned’s Shares (i) as a
bona fide gift or gifts, provided that the donee or donees thereof agree to be bound in writing by
the restrictions set forth herein, (ii) to any trust for the direct or indirect benefit of the
undersigned or the immediate family of the undersigned, provided that the trustee of the trust
agrees to be bound in writing by the restrictions set forth herein, and provided further that any
such transfer shall not involve a disposition for value, (iii) to limited partners or stockholders
of the undersigned, provided that each distributee agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a
disposition for value, (iv) in transactions relating to shares of Common Stock of the Company or
other securities acquired in open market transactions after the completion of the Public Offering,
(v) as a pledge in a bona fide loan transaction, provided that the pledgee or pledgees agree to be
bound in writing by the restrictions set forth herein, (vi) in an exercise of options pursuant to
the Company’s 2005 Stock Incentive Plan, provided that the shares of Common Stock of the Company
received upon such exercise shall be subject to the restrictions set forth herein or (vii) with the
prior written consent of GunnAllen Financial, Inc. For purposes of this Lock-Up Agreement,
“immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than
first cousin. In addition, notwithstanding the foregoing, if the undersigned is a corporation, the
corporation may transfer the capital stock of the Company to any wholly-owned subsidiary of such
corporation; provided, however, that in any such case, it shall be a condition to
the transfer that the
B-1
transferee execute an agreement stating that the transferee is receiving and holding such capital
stock subject to the provisions of this Agreement and there shall be no further transfer of such
capital stock except in accordance with this Agreement, and provided further that any such transfer
shall not involve a disposition for value. The undersigned also agrees and consents to the entry
of stop transfer instructions with the Company’s transfer agent and registrar against the transfer
of the Undersigned’s Shares except in compliance with the foregoing restrictions.
It is understood that, (i) if the Company notifies you that it does not intend to proceed with
the Public Offering, (ii) if the registration statement filed with the SEC with respect to the
Public Offering is withdrawn, (iii) if the Underwriting Agreement does not become effective by
September 30, 2005, or (iv) if the Underwriting Agreement (other than the provisions thereof which
survive termination) shall terminate or be terminated prior to payment for and delivery of the
Shares, this Agreement will terminate automatically and the undersigned will be released
automatically from the undersigned’s obligations under this Lock-Up Agreement.
The undersigned hereby represents that the undersigned has full power and authority to enter
into this Lock-Up Agreement, that the information set forth below is true and complete, and that
upon request, the undersigned will execute any additional documents necessary or desirable in
connection with the enforcement hereof. The undersigned understands that the Company and the
Underwriters are relying upon this Lock-Up Agreement in proceeding toward consummation of the
Public Offering. The undersigned further understands that this Lock-Up Agreement is irrevocable
and shall be binding upon the undersigned’s heirs, legal representatives, successors, and assigns.
Very truly yours,
Exact Name of Shareholder(s)
Authorized Signature
Authorized Signature if held jointly
Date
Address
Number of shares of Common Stock of the Company owned
Number of shares of Common Stock of the Company that may
be acquired pursuant to warrants, options or
convertible securities
Exact Name of Shareholder(s)
Authorized Signature
Authorized Signature if held jointly
Date
Address
Number of shares of Common Stock of the Company owned
Number of shares of Common Stock of the Company that may
be acquired pursuant to warrants, options or
convertible securities
B-2
Exhibit C
FORM OF COMMON STOCK PURCHASE WARRANT
TO PURCHASE __________ SHARES OF
COMMON STOCK OF BABYUNIVERSE, INC.
COMMON STOCK OF BABYUNIVERSE, INC.
UNDER NASD RULE 2710(g) AND SUBJECT TO LIMITED EXCEPTIONS, THIS WARRANT AND THE UNDERLYING
SHARES OF COMMON STOCK SHALL NOT BE SOLD DURING THE INITIAL PUBLIC OFFERING OF THE COMMON STOCK OF
BABYUNIVERSE, INC. OR SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR BE THE SUBJECT OF
ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE
ECONOMIC DISPOSITION OF THIS WARRANT OR THE SECURITIES UNDERLYING THIS WARRANT BY ANY PERSON FOR A
PERIOD OF 180 DAYS IMMEDIATELY FOLLOWING THE DATE OF EFFECTIVENESS OF OR COMMENCEMENT OF SALES IN
SUCH INITIAL PUBLIC OFFERING.
THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [GunnAllen Financial,
Inc./Wedbush Xxxxxx Securities Inc.] (the “Holder”) is entitled, upon the terms and subject
to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
February ___, 2006 (the “Initial Exercise Date”) and on or prior to the close of business on
[August 2, 2010] (the “Termination Date”) but not thereafter, to subscribe for and purchase
from BabyUniverse, Inc., a corporation incorporated in the State of Florida (the
“Company”), up to [130,000 in the aggregate under all Warrants] shares of common stock, par
value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one
share of Common Stock under this Warrant shall be $___[125% of the initial public offering
price], subject to adjustment hereunder (the “Exercise Price”). “Warrant” as used
herein shall include this common stock purchase warrant and any warrants delivered in substitution
or exchange therefor as provided herein.
1. Title to Warrant. Prior to the Termination Date and subject to the transfer
restrictions imposed by Rule 2710(g) of the National Association of Securities Dealers, Inc. (the
“NASD”) as set forth in the above legend and Section 7 hereof, this Warrant and all
rights hereunder are transferable, in whole or in part, at the office or agency of the Company by
the Holder in person or by duly authorized attorney, upon surrender of this Warrant together with
the Assignment Form annexed hereto properly endorsed.
2. Authorization of Shares. The Company covenants that all shares of Common Stock (or
other securities to which Holder is entitled pursuant to Section 11 or Section 12
hereof) which may be issued upon the exercise of the purchase rights represented by this Warrant
(the “Warrant Shares”) will, upon exercise of the purchase rights represented by this Warrant, be
duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and
charges in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue).
C-1
3. Exercise of Warrant.
(a) Except as provided in Section 4 herein, the purchase rights represented by this
Warrant may be exercised in whole or in part, at any time, or from time to time, on or after the
Initial Exercise Date and on or before the Termination Date, by delivering this Warrant and the
Notice of Exercise Form annexed hereto duly executed to the office of the Company (or such other
office or agency of the Company as it may designate by notice in writing to the registered Holder
at the address of such Holder appearing on the books of the Company) and by payment of the Exercise
Price of the shares thereby purchased by wire transfer, cash or check.
(b) In lieu of the payment of the Exercise Price, the Holder may require the Company to
convert this Warrant, in whole or in part, into shares of Common Stock (the “Conversion
Right”) as provided for in this Section 3. Upon exercise of the Conversion Right, the
Company shall deliver to the Holder (without payment by the Holder of any of the Exercise Price)
that number of shares of Common Stock (the “Conversion Shares”) equal to the quotient
obtained by dividing (x) the value of this Warrant (or portion thereof as to which the Conversion
Right is being exercised if the Conversion Right is being exercised in part) at the time the
Conversion Right is exercised (determined by subtracting the aggregate Exercise Price of the shares
of Common Stock as to which the Conversion Right is being exercised in effect immediately prior to
the exercise of the Conversion Right from the aggregate Current Market Price (as defined below) of
the shares of Common Stock as to which the Conversion Right is being exercised immediately prior to
the exercise of the Conversion Right) by (y) the Current Market Price of one share of Common Stock
immediately prior to the exercise of the Conversion Right. The Conversion Rights provided under
this Section 3(b) may be exercised, in whole or in part, at any time and from time to time,
while any Warrants remain outstanding. In order to exercise the Conversion Right, the Holder shall
surrender to the Company, at its offices, this Warrant with the Cashless Exercise Form at the end
hereof duly executed. The presentation and surrender shall be deemed a waiver of the Holder’s
obligation to pay all or any portion of the aggregate purchase price payable for the shares of
Common Stock as to which such Conversion Right is being exercised. This Warrant (or so much thereof
as shall have been surrendered for conversion) shall be deemed to have been converted immediately
prior to the close of business on the day of surrender of such Warrant for conversion in accordance
with the foregoing provisions. For the purposes of any computation under this Section
3(b), the term “Current Market Price” per share of Common Stock on any date shall be deemed to
be the average of the daily closing prices for the five consecutive trading days immediately
preceding the date in question. The closing price for each day shall be the last reported sales
price regular way or, in case no such reported sale takes place on such day, the closing bid price
regular way, in either case on the principal national securities exchange (including, for purposes
hereof, the National Market System of The Nasdaq Stock Market, Inc.) on which the Common Stock is
listed or admitted to trading or, if the Common Stock is not listed or admitted to trading on any
national securities exchange, the highest reported bid price for the Common Stock as furnished by
the National Association of Securities Dealers, Inc. through Nasdaq or a similar organization if
Nasdaq is no longer reporting such information. If on any such date the Common Stock is not listed
or admitted to trading on any national securities exchange and is not quoted by Nasdaq or any
similar organization, the fair value of a share of Common Stock on such date, as determined in good
faith by the board of directors of the Company, whose determination shall be conclusive absent
manifest error, shall be used.
C-2
(c) Warrant Shares purchased hereunder shall be delivered to the Holder within three (3)
business days after the date on which this Warrant shall have been exercised as aforesaid. This
Warrant shall be deemed to have been exercised and such certificate or certificates shall be deemed
to have been issued, and the Holder or any other person so designated to be named therein shall be
deemed to have become a holder of record of such shares for all purposes, as of the date the
Warrant has been exercised by payment to the Company of the Exercise Price. If eligible, the
Warrant Shares shall be delivered by the Company to the Holder via the Depository Trust Company’s
(“DTC”) Deposit Withdrawal Agent Commission (“DWAC”) system via the DTC
instructions provided to the Company in the Notice of Exercise. If the Company fails to deliver
the Warrant Shares to the Holder pursuant to this Section 3 by the close of business on the
third (3rd) business day after the date of exercise, then the Holder will have the right
to rescind such exercise. In addition to any other rights available to the Holder, if the Company
fails to deliver to the Holder a certificate or certificates representing the Warrant Shares
pursuant to an exercise by the close of business on the third (3rd) business day after
the date of exercise, and if after such third (3rd) business day the Holder is required
by its broker to purchase (in an open market transaction or otherwise) shares of Common Stock to
deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a “Buy-In”), then the Company shall (i) pay in cash to the
Holder the amount by which (A) the Holder’s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased exceeds (B) the amount obtained by multiplying
(x) the number of Warrant Shares that the Company was required to deliver to the Holder in
connection with the exercise at issue times (y) the price at which the sell order giving rise to
such purchase obligation was executed, and (ii) at the option of the Holder, either reinstate the
portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not
honored or deliver to the Holder the number of shares of Common Stock that would have been issued
had the Company timely complied with its exercise and delivery obligations hereunder. For example,
under clause (i) of the immediately preceding sentence, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000,
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In, together with
applicable confirmations and other evidence reasonably requested by the Company. Nothing herein
shall limit Holder’s right to pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Company’s failure to timely deliver certificates representing shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.
(d) If this Warrant shall have been exercised in part, the Company shall, at the time of
delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new
Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by
this Warrant, which new Warrant shall in all other respects be identical with this Warrant.
4. No Fractional Shares or Scrip. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share
which Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay a
cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by
the Exercise Price.
C-3
5. Charges and Expenses. Issuance of certificates for Warrant Shares shall be made
without charge to the Holder for any issue or transfer tax or other incidental expense in respect
of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company,
and such certificates shall be issued in the name of the Holder or in such name or names as may be
directed by the Holder; provided, however, that in the event certificates for
Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
by the Holder.
6. Closing of Books. The Company will not close its stockholder books or records in
any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.
7. Transfer, Division and Combination.
(a) This Warrant may not be sold, transferred, assigned or hypothecated without the Company’s
written consent, except that it may be transferred, in whole or in part, to (i) one or more
officers, members, employees, associates or subcontractors of the Holder (or the officers, members
or employees of any such member); (ii) any other underwriting firm or member of the selling group
which participated in the public offering of Common Stock (the “Offering”) which commenced on
August _, 2005 (or the officers, members or employees of any such firm); (iii) a successor to the
Holder, or the officers, members or employees of such successor; (iv) a purchaser of substantially
all of the assets of the Holder; or (v) by operation of law; and the term the “Holder” as used
herein shall include any transferee to whom this Warrant has been transferred in accordance with
the above; provided that (A) that the Holder or the transferee of this Warrant furnish to the
Company a written opinion of counsel, reasonably satisfactory to the Company, to the effect that
such transfer, assignment or hypothecation may be made without registration under the Securities
Act of 1933, as amended (the “Securities Act”) and under applicable state securities or
blue sky laws and (B) a written undertaking executed by the desired transferee reasonably
satisfactory to the Company in form and substance agreeing to be bound by the restrictions on
transfer contained herein; and further provided that no such opinion or written undertaking shall
be required in connection with a transfer, assignment or hypothecation pursuant to Rule 144 under
the Securities Act.
(b) In order to transfer this Warrant , in whole or in part, as permitted herein, this Warrant
must be surrendered at the principal office of the Company, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or
attorney. Upon such surrender, the Company shall execute and deliver a new Warrant or Warrants in
the name of the assignee or assignees and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of
this Warrant not so assigned, and this Warrant shall promptly be cancelled. A Warrant, if properly
assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued.
(c) Subject to the transfer restrictions imposed by NASD Rule 2710(g) as set forth in the
legend hereto and Section 7(a), this Warrant may be divided or combined with other Warrants
upon presentation hereof at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued, signed by the Holder
or its agent or attorney. Subject to compliance with Section 7(a) and 7(b),
C-4
as to any transfer which may be involved in such division or combination, the Company shall
execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice.
(d) The Company shall prepare, issue and deliver at its own expense the new Warrant or
Warrants under this Section 7.
(e) The Company agrees to maintain, at its aforesaid office, books for the registration and
the registration of transfer of Warrants.
8. No Rights as Shareholder until Exercise. This Warrant does not entitle the Holder
to any voting rights or other rights as a shareholder of the Company prior to the exercise hereof.
Upon the surrender of this Warrant and the payment of the aggregate Exercise Price (or by means of
a cashless exercise), the Warrant Shares so purchased shall be and be deemed to be issued to such
Holder as the record owner of such shares as of the close of business on the later of the date of
such surrender or payment.
9. Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon
receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or
mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of
loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the
case of the Warrant, shall not include the posting of any bond), and upon surrender and
cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver
a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such
Warrant or stock certificate.
10. Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall be a Saturday, Sunday or
a legal holiday on which banks in the United States are closed, then such action may be taken or
such right may be exercised on the next succeeding day which is not a Saturday, Sunday or legal
holiday.
11. Adjustments of Exercise Price and Number of Warrant Shares; Stock Splits, etc.
The number and kind of securities purchasable upon the exercise of this Warrant and the Exercise
Price shall be subject to adjustment from time to time upon the happening of any of the following:
In case the Company shall (a) pay a dividend in shares of Common Stock or make a distribution in
shares of Common Stock to holders of its outstanding Common Stock, (b) subdivide its outstanding
shares of Common Stock into a greater number of shares, (c) combine its outstanding shares of
Common Stock into a smaller number of shares of Common Stock, or (d) issue any shares of its
capital stock in a reclassification of the Common Stock, then the number of Warrant Shares
purchasable upon exercise of this Warrant immediately prior thereto shall be adjusted so that the
Holder shall be entitled to receive the kind and number of Warrant Shares or other securities of
the Company which it would have owned or have been entitled to receive had such Warrant been
exercised in advance thereof. Upon each such adjustment of the kind and number of Warrant Shares
or other securities of the Company which are purchasable hereunder, the Holder shall thereafter be
entitled to purchase the number of Warrant Shares or other securities resulting from such
adjustment at an Exercise Price per Warrant Share or other security obtained by multiplying the
Exercise Price in effect immediately prior to such
C-5
adjustment by the number of Warrant Shares purchasable pursuant hereto immediately prior to
such adjustment and dividing by the number of Warrant Shares or other securities of the Company
resulting from such adjustment. An adjustment made pursuant to this paragraph shall become
effective immediately after the effective date of such event retroactive to the record date, if
any, for such event.
12. Reorganization, Reclassification, Merger, Consolidation or Disposition of Assets.
In case the Company shall reorganize its capital, reclassify its capital stock, consolidate or
merge with or into another entity (where the Company is not the surviving entity or where there is
a change in or distribution with respect to the Common Stock of the Company), or sell, transfer or
otherwise dispose of all or substantially all its property, assets or business to another entity
and, pursuant to the terms of such reorganization, reclassification, merger, consolidation or
disposition of assets, shares of common stock of the successor or acquiring entity, or any cash,
shares of stock or other securities or property of any nature whatsoever (including warrants or
other subscription or purchase rights) in addition to or in lieu of common stock of the successor
or acquiring entity (“Other Property”), are to be received by or distributed to the holders
of Common Stock of the Company, then the Holder shall have the right thereafter to receive, upon
exercise of this Warrant, instead of the shares of Common Stock, the number of shares of common
stock and/or Other Property receivable upon or as a result of such reorganization,
reclassification, merger, consolidation or disposition of assets by Holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such event. In case of
any such reorganization, reclassification, merger, consolidation or disposition of assets, the
successor or acquiring entity (if other than the Company) shall expressly assume the due and
punctual observance and performance of each and every covenant and condition of this Warrant to be
performed and observed by the Company and all the obligations and liabilities hereunder, subject to
such modifications as may be deemed appropriate (as determined in good faith by resolution of the
Board of Directors of the Company) in order to provide for adjustments of Warrant Shares for which
this Warrant is exercisable which shall be as nearly equivalent as practicable to the adjustments
provided for in this Section 12. For purposes of this Section 12, “common stock”
of a corporation shall include stock of such corporation of any class which is not preferred as to
dividends or assets over any other class of stock of such corporation and which is not subject to
redemption and shall also include any evidences of indebtedness, shares of stock or other
securities which are convertible into or exchangeable for any such stock, either immediately or
upon the arrival of a specified date or the happening of a specified event and any warrants or
other rights to subscribe for or purchase any such stock. The foregoing provisions of this
Section 12 shall similarly apply to successive reorganizations, reclassifications, mergers,
consolidations or disposition of assets.
13. Voluntary Adjustment by the Company. The Company may at any time during the term
of this Warrant reduce the then current Exercise Price to any amount and for any period of time
deemed appropriate by the Board of Directors of the Company.
14. Notice of Adjustment. Whenever the number of Warrant Shares or number or kind of
securities or other property purchasable upon the exercise of this Warrant or the Exercise Price is
adjusted, as herein provided, the Company shall give notice thereof to the Holder, which notice
shall state the number of Warrant Shares (and/or other securities or property) purchasable upon the
exercise of this Warrant and the Exercise Price of such Warrant Shares (and/or other
C-6
securities or property) after such adjustment, setting forth a brief statement of the facts
requiring such adjustment and setting forth the computation by which such adjustment was made.
15. Notice of Corporate Action. If at any time:
(a) the Company shall take a record of the holders of its Common Stock for the purpose of
entitling them to receive an extraordinary dividend or other distribution, or any right to
subscribe for or purchase any evidences of its indebtedness, any shares of stock of any class or
any other securities or property, or to receive any other right, or
(b) there shall be any capital reorganization of the Common Stock, any reclassification or
recapitalization of the capital stock of the Company or any consolidation or merger of the Company
with, or any sale, transfer or other disposition of all or substantially all the property, assets
or business of the Company to, another entity, or
(c) there shall be a voluntary or involuntary dissolution, liquidation or winding up of the
Company, or
(d) the loss of effectiveness or availability for use of the Registration Statement (as
defined herein), as reasonably determined by the Company;
then, in any one or more of such cases, the Company shall give to Holder (i) at least 10 days’
prior written notice of the date on which a record date shall be selected for such dividend,
distribution or right or for determining rights to vote in respect of any such reorganization,
reclassification, merger, consolidation, sale, transfer, disposition, liquidation or winding up,
and (ii) in the case of any such reorganization, reclassification, merger, consolidation, sale,
transfer, disposition, dissolution, liquidation or winding up, at least 10 days’ prior written
notice of the date when the same shall take place, and (iii) in the case of the loss of
effectiveness or availability for use of the Registration Statement, promptly upon knowledge by the
Company of such occurrence. Such notice in accordance with the foregoing clauses (a)-(c) also
shall specify (i) the date on which any such record is to be taken for the purpose of such
dividend, distribution or right, the date on which the holders of Common Stock shall be entitled to
any such dividend, distribution or right, and the amount and character thereof, and (ii) the date
on which any such reorganization, reclassification, merger, consolidation, sale, transfer,
disposition, dissolution, liquidation or winding up is to take place and the time, if any such time
is to be fixed, as of which the holders of Common Stock shall be entitled to exchange their Warrant
Shares for securities or other property deliverable upon such disposition, dissolution, liquidation
or winding up. Such notice in accordance with clause (d) shall also specify the Company’s good
faith belief as to when a registration statement registering such sale shall be filed or amended or
available for use again. Each such written notice shall be sufficiently given if addressed to
Holder at the last address of Holder appearing on the books of the Company and delivered in
accordance with Section 18(e).
16. Authorized Shares; No Impairment; Authorizations. The Company covenants that
during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon
the exercise of any purchase rights under this Warrant. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are charged with
C-7
the duty of executing stock certificates to execute and issue the necessary certificates for
the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will
take all such reasonable action as may be necessary to assure that such Warrant Shares may be
issued as provided herein without violation of any applicable law or regulation, or of any
requirements of the principal market or exchange upon which the Common Stock may be listed.
Except and to the extent as waived or consented to by the Holder, the Company shall not by any
action, including, without limitation, amending its certificate of incorporation or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to protect the
rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in par value, (b)
take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and
(c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary to enable the
Company to perform its obligations under this Warrant.
Before taking any action which would result in an adjustment in the number of Warrant Shares
for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such
authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof.
17. Registration Rights.
(a) At any time on or after the Initial Exercise Date but not after the Termination Date,
Holder shall have the right to request that the Company file with the U.S. Securities and Exchange
Commission (the “SEC”) a registration statement covering the resale of the Warrant Shares
for an offering to be made on a continuous basis pursuant to Rule 415 or registering the sale of
the Warrant Shares to the Holder upon exercise of this Warrant (the “Registration
Statement”); provided, however, the Company shall not have any obligation to
file a Registration Statement if, at such time, all of the Warrant Shares could be sold by Holder
without volume restrictions pursuant to Rule 144(k) promulgated under the Securities Act of 1933,
as amended (the “Securities Act”), as determined by legal counsel pursuant to a written
opinion to such effect addressed and acceptable to Holder and the Company’s transfer agent. Upon
such request, Company shall file within thirty (30) days of such request (the “Filing
Deadline”) the Registration Statement required hereunder and shall use its commercially
reasonable best efforts to effect as soon as practicable, and in any event within ninety (90) days
of the receipt of such request, the registration under the Securities Act of all of the Warrant
Shares. The Company shall pay all costs and expenses related to the registration of the Warrant
Shares. The Company shall use its commercially reasonable best efforts to keep such Registration
Statement continuously effective under the Securities Act, until all Warrant Shares covered by such
Registration Statement have been sold or may be sold without volume restrictions pursuant to
C-8
Rule 144(k), as determined by legal counsel pursuant to a written opinion to such effect
addressed and acceptable to Holder and the Company’s transfer agent.
(b) If the Registration Statement is not filed with the SEC on or before the Filing Deadline
or, in the event the Registration Statement is reviewed by the SEC, if the Company does not submit
written responses to the SEC within ten (10) business days after receipt of comments to the
Registration Statement from the SEC (thirty (30) calendar days in the event the SEC requires
material changes to or a restatement of the Company’s financial statements), the Company shall pay
to Holder an amount equal to the product of (i) the Exercise Price multiplied by (ii) 2.0% for each
30-day period (or pro rata portion thereof) after the Filing Deadline and prior to the date the
Registration Statement is filed with the SEC or after the ten (10) business day (or thirty (30)
calendar days, as applicable) period after the Company receives the SEC’s comments to the
Registration Statement and prior to the date the Company submits written responses to such
comments, as the case may be; provided that the Company may delay (an “Allowed Delay”) the initial
filing of any requested Registration Statement hereunder or any required updating of the
Registration Statement (during which updating period the parties agree that the Registration
Statement shall not be used for resales until an appropriate prospectus supplement is filed or an
appropriate amendment, if required, is declared effective by the SEC), for not more than fifteen
(15) consecutive trading days (or a total of 45 trading days during any twelve (12) month period),
if the Company’s board of directors determines in good faith that such filing with the SEC would
require the premature disclosure of material nonpublic information concerning the Company. After a
Registration Statement becomes effective, if an Allowed Delay occurs the Company shall advise the
Holders to cease all sales under the Registration Statement until the end of the Allowed Delay.
(c) The Company shall, not less than three (3) business days prior to the filing of the
Registration Statement or any related prospectus or any amendment or supplement thereto, (i)
furnish to Holder copies of the Registration Statement or prospectus proposed to be filed, which
documents will be subject to the review of such Holder, and (ii) cause its officers and directors,
counsel and independent certified public accountants to respond to such inquiries as shall be
necessary, in the reasonable opinion of respective counsel to conduct a reasonable investigation
within the meaning of the Securities Act. Furthermore, the Company shall advise Holder, within two
(2) business days: (x) after it shall receive notice or obtain knowledge of the issuance of any
stop order by the SEC delaying or suspending the effectiveness of the Registration Statement or of
the initiation or threat of any proceeding for that purpose, or any other order issued by any state
securities commission or other regulatory authority suspending the qualification or exemption from
qualification of such Warrant Shares under state securities or “blue sky” laws; and it will
promptly use its best efforts to prevent the issuance of any stop order or other order or to obtain
its withdrawal at the earliest possible moment if such stop order or other order should be issued;
and (y) when the prospectus or any prospectus supplement or post-effective amendment has been
filed, and, with respect to the Registration Statement or any post-effective amendment thereto,
when the same has become effective.
(d) In addition at any time prior [August 2, 2012], Holder shall be entitled to unlimited
“piggyback” registration rights such that if the Company proposes to register (including for this
purpose a registration effected by the Company for security holders other than Holder) any of its
stock or other securities under the Securities Act in connection with the public
C-9
offering of such securities solely for cash (other than a registration relating solely to the
sale of securities to participants in a Company stock plan, a registration on any form which does
not include substantially the same information as would be required to be included in a
registration statement covering the sale of the Warrant Shares), the Company shall, at such time,
promptly give Holder written notice (the “Company’s Notice”) of such registration. Upon
the written request of Holder given within twenty (20) days of the Company’s Notice, the Company
shall cause to be registered under the Securities Act all of the Warrant Shares that such Holder
has requested to be registered; provided, however, if such public offering is to be
underwritten and, in the good faith judgment of the managing underwriter, the inclusion of all of
the Warrant Shares that such Holder has requested to be registered would interfere with the
successful marketing of a smaller number of such shares of the Company’s stock or other securities,
the number of Warrant Shares to be included in such public offering shall be reduced as determined
in the good faith judgment of such managing underwriter; provided, further, that
the managing underwriter shall reduce, limit or exclude securities for registration in the
following order: (i) first, among securities requested to be included in such registration by any
person who does not have a contractual right to request registration of such securities; (ii)
second, pro rata among the securities requested to be included in such registration by persons with
a right to request registration of such securities, on the basis of the number of securities owned
by such holders requesting inclusion in the registration; and (iii) third, among the securities
which the Company proposes to sell. Upon request by the managing underwriter of such offering, any
Warrant Shares that are thereby excluded from the offering shall be withheld from the market by the
Holder for a period (not to exceed 30 days prior to the effective date and 90 days thereafter) that
the managing underwriter reasonably determines is necessary in order to successfully complete the
underwritten public offering; provided, however, that the foregoing restrictions
shall not apply to Holder unless all officers and directors of the Company and all holders of one
percent or more of the Company’s outstanding capital stock and all holders with registration rights
of any kind are bound by similar agreements or restrictions.
(e) (i) The Company agrees to indemnify and hold harmless each Holder Indemnitee (as defined
below) from and against any losses, claims, damages, liabilities or expenses to which such Holder
Indemnitee may become subject (under the Securities Act or otherwise) insofar as such losses,
claims, damages, liabilities or expenses (or actions or proceedings in respect thereof) arise out
of, or are based upon (A) any untrue statement of a material fact contained in the Registration
Statement or prospectus, (B) any failure by the Company to fulfill any undertaking included in the
Registration Statement, (C) any breach of any representation, warranty or covenant made by the
Company in this Warrant and (D) any violation or alleged violation of the Securities Act, the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), any other law, including,
without limitation, any state securities law, or any rule or regulation thereunder relating to the
offer or sale of the Warrant Shares (but excluding claims arising from a failure of the Holder to
deliver the prospectus timely provided by the Company in compliance with applicable securities
laws, where such failure to deliver was the cause of such claim or would have corrected the alleged
damage), and the Company will promptly reimburse such Holder Indemnitee for any reasonable legal or
other expenses incurred in investigating, defending or preparing to defend, settling, compromising
or paying any such action, proceeding or claim; provided, however, that the Company
shall not be liable in any such case to the extent that such loss, claim, damage, liability or
expense arises solely out of, or is based solely upon, an untrue statement made in such
Registration Statement in reliance upon and in conformity with
C-10
written information furnished to the Company by such Holder Indemnitee specifically for use in
preparation of the Registration Statement.
(ii) The Holder agrees (severally and not jointly with any other Holder) to indemnify and hold
harmless the Company (and each person, if any, who controls the Company within the meaning of
Section 15 of the Securities Act, each officer of the Company who signs the Registration Statement
and each director of the Company) from and against any losses, claims, damages, liabilities or
expenses to which the Company (or any such officer, director or controlling person) may become
subject (under the Securities Act or otherwise), insofar as such losses, claims, damages,
liabilities or expenses (or actions or proceedings in respect thereof) arise solely out of, or are
based solely upon, any untrue statement of a material fact contained in the Registration Statement,
but only if and to the extent that such untrue statement was made in reliance upon and in
conformity with written information furnished by the Holder specifically for use in preparation of
the Registration Statement (provided, however, that the Holder shall not be liable
in any such case for any untrue statement in any Registration Statement or prospectus if such
statement has been corrected in writing by such Holder and delivered to the Company at least three
business days prior to the pertinent sale or sales by the Holder). Notwithstanding the foregoing,
the Holder’s aggregate liability pursuant to this subsection (ii) shall be limited to the net
amount received by the Holder from the sale of the Warrant Shares.
(iii) Promptly after receipt by any indemnified person of a notice of a claim or the beginning
of any action in respect of which indemnity is to be sought against an indemnifying person pursuant
to this Section 17(e), such indemnified person shall notify the indemnifying person in
writing of such claim or of the commencement of such action, but the omission to so notify the
indemnifying party will not relieve it from any liability which it may have to any indemnified
party under this Section 17(e) (except to the extent that such omission materially and
adversely affects the indemnifying party’s ability to defend such action) or from any liability
otherwise than under this Section 17(e). Subject to the provisions hereinafter stated, in
case any such action shall be brought against an indemnified person, the indemnifying person shall
be entitled to participate therein, and, to the extent that it shall elect by written notice
delivered to the indemnified party promptly after receiving the aforesaid notice from such
indemnified party, shall be entitled to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified person. After notice from the indemnifying person to such
indemnified person of its election to assume the defense thereof, such indemnifying person shall
not be liable to such indemnified person for any legal expenses subsequently incurred by such
indemnified person in connection with the defense thereof, provided however, that
if there exists or shall exist a conflict of interest that would make it inappropriate, in the
opinion of counsel to the indemnifying person, for the same counsel to represent both the
indemnified person and such indemnifying person or any affiliate or associate thereof, the
indemnified person shall be entitled to retain its own counsel at the expense of such indemnifying
person; provided, however, that no indemnifying person shall be responsible for the
fees and expenses of more than one separate counsel (together with appropriate local counsel) for
all indemnified parties. In no event shall any indemnifying person be liable in respect of any
amounts paid in settlement of any action unless the indemnifying person shall have approved the
terms of such settlement; provided, that such consent shall not be unreasonably withheld.
No indemnifying person shall, without the prior written consent of the indemnified person, effect
any settlement of any pending or threatened proceeding in respect of which any indemnified person
is or could have been a party
C-11
and indemnification could have been sought hereunder by such indemnified person, unless such
settlement includes an unconditional release of such indemnified person from all liability on
claims that are the subject matter of such proceeding.
(iv) If the indemnification provided for in this Section 17(e) is unavailable to or
insufficient to hold harmless an indemnified party under subsection (A) or (B) above in respect of
any losses, claims, damages, liabilities or expenses (or actions or proceedings in respect thereof)
referred to therein, then each indemnifying party shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages, liabilities or expenses (or
actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of
the Company on the one hand and the Holder on the other in connection with the statements or
omissions or other matters which resulted in such losses, claims, damages, liabilities or expenses
(or actions in respect thereof), as well as any other relevant equitable considerations. The
relative fault shall be determined by reference to, among other things, in the case of an untrue
statement, whether the untrue statement relates to information supplied by the Company on the one
hand or the Holder on the other and the parties’ relative intent, knowledge, access to information
and opportunity to correct or prevent such untrue statement. The Company and the Holders agree
that it would not be just and equitable if contribution pursuant to this subsection (iv) were
determined by pro rata allocation (even if Holder and any other Holders were treated as one entity
for such purpose) or by any other method of allocation which does not take into account the
equitable considerations referred to above in this subsection (iv). The amount paid or payable by
an indemnified party as a result of the losses, claims, damages or liabilities (or actions in
respect thereof) referred to above in this subsection (iv) shall be deemed to include any legal or
other expenses reasonably incurred by such indemnified party in connection with investigating or
defending any such action or claim. Notwithstanding the provisions of this subsection (iv), Holder
shall not be required to contribute any amount in excess of the net amount received by the Holder
from the sale of the Warrant Shares. No person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation. Holder’s obligations in this subsection
to contribute are several in proportion to its sales of Warrant Shares to which such loss relates
and not joint with any other Holders.
(v) For purposes of this Section 17(e), the term “Holder Indemnitee” shall
include the Holder, its officers, directors, employees, partners, agents and any person controlling
such Holder; the term “Registration Statement” shall include any final prospectus, exhibit,
supplement or amendment included in or relating to the Registration Statement; and the term
“untrue statement” shall include (A) any untrue statement or alleged untrue statement, or
any omission or alleged omission to state in the Registration Statement a material fact required to
be stated therein or necessary to make the statements therein not misleading and (B) any untrue
statement or alleged untrue statement, or any omission or alleged omission to state in the
prospectus a material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.
18. Miscellaneous.
(a) Jurisdiction. This Warrant shall be governed by and construed in accordance with
the laws of the state of Florida as applied to contracts among Florida residents made and to be
C-12
performed entirely within the state of Florida, without regard to its conflict of law
principles or rules.
(b) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the
exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state
and federal securities laws.
(c) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise
any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise
prejudice Holder’s rights, powers or remedies, notwithstanding all rights hereunder terminate on
the Termination Date. If the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder
such amounts as shall be sufficient to cover any costs and expenses including, but not limited to,
reasonable attorneys’ fees, including those of appellate proceedings, incurred by Holder in
collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or
remedies hereunder.
(d) NASD Rules. Notwithstanding anything contained in this Warrant, the terms of this
Warrant are intended to comply with the rules and regulations of the NASD relating to the
compensation of underwriters and placement agents, and any provision of this Warrant that is
determined to be inconsistent with such rules shall be deemed to be modified to the extent
necessary to comply with such rules.
(e) Notices. Except as otherwise provided herein, any notice or request required or
permitted to be given or delivered to the Holder by the Company shall be given in writing and shall
be deemed effectively given (i) upon personal delivery to Holder, (ii) when sent by electronic mail
or confirmed facsimile if sent during normal business hours of Holder, and if not sent during
normal business hours, then on the next business day, (iii) five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All such notices or requests shall be sent to: [GunnAllen Financial,
Inc., 0000 Xxxx Xxxxxx Xxxxxx, Xxxxx, XX 00000, Facsimile No. (000)000-0000, Attn:
___/Wedbush Xxxxxx Securities Inc., 0000 Xxxxxxxx Xxxxxxxxx, Xxx Xxxxxxx, XX 00000,
Facsimile No. (000)000-0000, Attn: ___].
(f) Limitation of Liability. No provision hereof, in the absence of any affirmative
action by Holder to exercise this Warrant or purchase Warrant Shares, and no enumeration herein of
the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.
(g) Remedies. Holder, in addition to being entitled to exercise all rights granted by
law, including recovery of damages, will be entitled to specific performance of its rights under
this Warrant. The Company agrees that monetary damages would not be adequate compensation for any
loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to
waive the defense in any action for specific performance that a remedy at law would be adequate.
C-13
(h) Successors and Assigns. Subject to applicable securities laws, this Warrant and
the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the
successors of the Company and the successors and permitted assigns of Holder. The provisions of
this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant Shares.
(i) Amendment. This Warrant may be modified or amended or the provisions hereof
waived with the written consent of the Company and the Holder; provided, however,
if this Warrant is subsequently transferred to other persons, this Warrant may be modified or
amended or the provisions hereof waived with the written consent of such transferees (and the
original Holder if such Holder holds any part of the Warrant at such time) holding Warrant(s)
exercisable into a majority of the Warrant Shares then issuable under the Warrants derived from the
initial Warrant.
(j) Severability. Wherever possible, each provision of this Warrant shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of
such provisions or the remaining provisions of this Warrant.
(k) Headings. The headings used in this Warrant are for the convenience of reference
only and shall not, for any purpose, be deemed a part of this Warrant.
[Remainder of page intentionally left blank]
C-14
IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized.
Dated: August__, 2005
BABYUNIVERSE, INC. |
||||
By: | /s/ | |||
Name: | ||||
Title: |
C-15
NOTICE OF EXERCISE
(1) The undersigned hereby elects to purchase ___Warrant Shares of BabyUniverse, Inc.
pursuant to the terms of the Common Stock Purchase Warrant dated August___, 2005 (which is attached
hereto), and tenders herewith payment of the exercise price in full.
(2) Please issue a certificate or certificates representing said Warrant Shares in the name
of the undersigned or in such other name as is specified below:
The Warrant Shares shall be delivered to the following DTC account:
[GUNNALLEN FINANCIAL, INC./WEDBUSH XXXXXX SECURITIES INC.] |
||||
By: | /s/ | |||
Name: | ||||
Title: | ||||
Dated: ___________________________
ASSIGNMENT FORM
(To assign the foregoing warrant, execute this form and supply required information.
Do not use this form to exercise the warrant.)
Do not use this form to exercise the warrant.)
FOR VALUE RECEIVED, the foregoing Common Stock Purchase Warrant dated August ___, 2005 and all
rights evidenced thereby are hereby assigned to
___whose address is
___.
Dated: ______________, _______
Holder’s Signature:
|
||
Holder’s Address:
|
||
To: | BabyUniverse, Inc. 0000 XX 0xx Xxxxxx Xxxxx 000 Xx. Xxxxxxxxxx, Xxxxxxx 00000 |
CASHLESS EXERCISE FORM
(To be executed upon conversion of the attached Warrant)
(To be executed upon conversion of the attached Warrant)
The undersigned hereby irrevocably elects to surrender its Warrant for the number of shares of
Common Stock as shall be issuable pursuant to the cashless exercise provisions set forth in Section
2 of the within Warrant, in respect of ___shares of Common Stock underlying the within
Warrant, and requests that certificates for such securities be issued in the name of and delivered
to:
(Print, Name, Address and Social Security
or Tax Identification Number)
or Tax Identification Number)
and, if such number of shares shall not be all the shares exchangeable or purchasable under the
within Warrant, that a new Warrant for the balance of the Warrant Shares covered by the within
Warrant be registered in the name of, and delivered to, the undersigned at the address stated
below.
Dated: |
Name |
Address: |
/s/ | ||||
(Signature) | ||||